The Impact of an Intronic Dopamine Receptor Type-2 Single Nucleotide Polymorphism on Growth, Reproduction and Prolactin Gene Expression in Beef Bulls by DeCarlo, Andrea
Clemson University 
TigerPrints 
All Dissertations Dissertations 
December 2019 
The Impact of an Intronic Dopamine Receptor Type-2 Single 
Nucleotide Polymorphism on Growth, Reproduction and Prolactin 
Gene Expression in Beef Bulls 
Andrea DeCarlo 
Clemson University, adecarl@g.clemson.edu 
Follow this and additional works at: https://tigerprints.clemson.edu/all_dissertations 
Recommended Citation 
DeCarlo, Andrea, "The Impact of an Intronic Dopamine Receptor Type-2 Single Nucleotide Polymorphism 
on Growth, Reproduction and Prolactin Gene Expression in Beef Bulls" (2019). All Dissertations. 2505. 
https://tigerprints.clemson.edu/all_dissertations/2505 
This Dissertation is brought to you for free and open access by the Dissertations at TigerPrints. It has been 
accepted for inclusion in All Dissertations by an authorized administrator of TigerPrints. For more information, 
please contact kokeefe@clemson.edu. 
 
 
 
 
 
 
 
THE IMPACT OF AN INTRONIC DOPAMINE RECEPTOR TYPE-2  
SINGLE NUCLEOTIDE POLYMORPHISM ON GROWTH, REPRODUCTION  
AND PROLACTIN GENE EXPRESSION IN BEEF BULLS 
 
 
A Dissertation 
Presented to 
the Graduate School of 
Clemson University 
 
 
In Partial Fulfillment 
of the Requirements for the Degree 
Doctor of Philosophy 
Animal & Veterinary Sciences 
 
 
by 
Andrea Nicole DeCarlo 
December 2019 
 
 
Accepted by: 
Dr. Scott L. Pratt, Committee Chair 
Dr. Nathan M. Long 
Dr. Thomas R. Scott 
Dr. William C. Bridges, Jr. 
 
 
 
 
 
 
 
 
 ii 
ABSTRACT 
 Prolactin (PRL) is a ~22 kDa peptide hormone reported to regulate over 300 distinct 
biological functions in vertebrates. Tonic inhibition of prolactin (PRL) by dopamine 
binding to dopamine receptor-type 2 (DRD2) is well established and changes in PRL serum 
concentration resulting in detrimental effects to male reproductive physiology have been 
observed. Release and synthesis of PRL may be altered due to a single nucleotide 
polymorphism (SNPs) in the DRD2 gene. The objective of these studies were to evaluate 
associations of a previously identified DRD2 SNP to PRL serum concentrations, growth 
traits, semen quality, and PRL gene expression in beef bulls. Semen quality, growth traits, 
and serum PRL concentrations were recorded from bulls exposed to a dopamine agonist 
over a 4-year study. Testis and epididymis were collected from bulls in Year 1 at the end 
of a 126 d study. Genotyping was performed on genomic DNA from semen samples by 
restriction fragment length polymorphism (RFLP) and Taqman custom SNP genotyping 
assays. Genotype was not associated with semen quality, serum PRL concentrations, or 
growth traits; however, treatment of a dopamine agonist lowered serum PRL 
concentrations. Immunohistochemistry revealed the presence of DRD2 in testis, 
epididymis and sperm cells. Prolactin protein expression, assessed by western blotting, 
indicated presence of PRL protein in only anterior pituitary. Pituitaries were collected from 
a local abattoir with selection of male posterior pituitaries performed by duplex PCR and 
Southern blotting methods. Genotyping was performed by RFLP for the DRD2 SNP. Slot 
blot and densitometry analysis for PRL protein expression was performed on a subset of 
male pituitaries (n = 92). No association between the DRD2 SNP and PRL protein 
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expression in bovine anterior pituitary was observed. Taken together, these data indicate 
no DRD2 SNP genotypic effect on growth or semen quality. Further, PRL protein 
expression was similar across genotype in the anterior pituitary, the main source of PRL 
synthesis and secretion. 
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CHAPTER ONE 
LITERATURE REVIEW 
 
Prolactin 
Structure 
Prolactin is a member of the GH/PRL gene family (Anthony et al., 1995). Prolactin 
cDNA has been characterized across a number of species including cattle, human, rat, and 
mouse (Wallis, 1974; Miller et al., 1981; Cooke et al., 1980; Linzer and Talamantes, 1985).  
to rat and humans, respectively (Miller et al., 1981). The PRL gene is made up of 5 exons 
separated by 4 introns (Miller et al., 1981; Truong et al., 1984). The PRL amino acid 
sequence characterized from cDNA for the coding region of the PRL gene, excluding pre-
sequences, share 60.5% identity between cattle and rats and 74% identity between cattle 
and humans (Miller et al., 1981). The cDNA characterized for the PRL gene coding region 
in cattle pituitary encoded for a protein of ~227 amino acids (~26 kDa) with a 28-nucleotide 
long signal peptide. Once the signal peptide is cleaved the mature PRL protein is ~199 
amino acids in length with a molecular weight of ~22 kDa (Wallis, 1974; Miller et al., 
1981). The sequence does not possess a traditional AAUAAA poly (A) region; however, 
Sasavage and others (1982) reported three poly (A) sites and suggested the possibility of 
multiple processing mechanisms through alternative polyadenylation, therefore producing 
multiple transcripts from the single gene (Sasavage et al., 1982). Camper and others (1984) 
determined PRL gene number by genomic titration of bovine pituitary DNA against a 
standard curve of genomic equivalents produced from a PRL cDNA clone. Genomic DNA 
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was blotted to a membrane in increasing concentrations and hybridized with a PRL-specific 
32P-labeled probe. Detection of signal was carried out by a scintillation counter. The curve 
was linear with 10 µg of pituitary DNA plotted at 1 genomic equivalent indicating a single 
copy gene per haploid genome (Camper et al., 1984). According to PRL cDNAs 
characterized across mammals all encode for a protein consisting of six conserved cysteine 
residues predicted to form 3 disulfide bonds making up a large central loop, and small N- 
and C-terminal loops (Wallis, 1974; Cooke et al., 1980; Miller et al., 1981; Linzer and 
Talamantes, 1985). 
 Variants of PRL form by proteolytic cleavage or upon reduction of disulfide bonds. 
Posttranslational processing results in cleaved PRL isoforms, 14 and 16 kDa in size 
(Freeman et al., 2000). The 16 kDa isoform has been reported in rat pituitary cells. 
Cleavage of the large central loop occurs at a Tyr145 to produce the 16 kDa isoform 
(Andries et al., 1992) possibly by proteases that are present in the anterior pituitary (DeVito 
et al., 1992). Cole and colleagues (1991) purified monkey and baboon PRL identifying a 
16 kDa PRL protein. They proposed a cleavage site at Ile133 that would theoretically result 
in a 14 kDa fragment. The 14 kDa fragment was confirmed as a posttranslational product 
of the native 23 kDa PRL, as RT-PCR and Southern analysis only revealed the 23 kDa 
PRL product, indicating the 14 kDa variant would actually be independent from the 16 kDa 
fragment. fragment was not a result of alternative splicing (Clapp et al., 1994). A year later 
Torner and colleagues (1995) confirmed the 14 kDa variant was the dominant form in rat 
hypothalamo-neurohypophyseal system (Torner et al., 1995). 
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Phosphorylation is the main post-translational modification of PRL proteins, with 
upwards of 80% of all PRL in the bovine pituitary phosphorylated (Kim and Brooks, 1993). 
Phosphorylation of PRL occurs predominantly at serine 90 residue but has also been shown 
to occur at two minor sites, ser26 and ser34. In Nb2 cell culture a PRL mixture of both 
nonphosphorylated and phosphorylated 125I bovine PRL was set up to compete for binding 
with either nonphosphorylated or phosphorylated bovine PRL. Phosphorylated PRL was 
not able to compete for binding of the intermediate PRL receptor present in Nb2 cell culture 
(Kelly et al., 1992) at concentrations up to 65 nM, indicating phosphorylation produces a 
less biologically active form of PRL (Wicks and Brooks, 1995).   
Glycosylated PRL (N-linked glycosylation) makes up as little as 15% of PRL in the 
pituitary of sheep and humans but upwards of 40% in swine (Sinha, 1992). Prolactin 
proteins are glycosylated through attachment of a carbohydrate at asparagine residue 31 in 
sheep and humans at a consensus sequence of Asn-X-Ser. Bovine pituitary possesses only 
a small portion of glycosylated PRL, approximately 1% due to the lack of a glycosylation 
sequence with an Asp in place of the Asn at residue 31, therefore glycosylated PRL is not 
prevalent in cattle at as low as 1% in the pituitary (Lewis et al., 1984; Sinha et al., 1995). 
Further, a cell-free protein synthesis system was utilized with isolated bovine pituitary 
microsomes to identify post-translational modification of bovine and ovine PRL. Protein 
extracts from bovine pituitaries did not contain glycosylated forms of PRL (Strickland and 
Pierce, 1985). Glycosylated PRL has been shown to elicit greater lactogenic but not 
mitogenic activity than non-glycosylated forms in swine (Young et al., 1990) and has been 
shown to impact metabolic clearance rate of PRL (Sinha et al., 1991). It is plausible that 
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cattle lack the N-linked glycosylation sites for regulation of PRL function through 
conformation, since addition of a carbohydrate moiety would alter conformation and 
therefore binding properties. Conformational changes as a result of glycosylation could 
play a role in dictating specificity for ligand receptor binding across species. An example 
of this species specificity is with human growth hormone receptors, which will only bind 
growth hormone from primate origin, but human growth hormone ligand will bind to other 
species’ growth hormone receptors (Li et al., 1957). Human glycosylated PRL exhibited 
weak competitive binding, comparable to bovine PRL in human kidney cells transfected 
with a hybrid human prolactin receptor (PRLR) containing a 5’rat untranslated sequence. 
(Lochnan et al., 1995). Therefore, the lack of N-glycosylation consensus sequence for post-
translational modification by glycosylation may be specific for bovine PRL to permit high 
affinity binding to bovine PRLR but not the human PRLR. 
Larger PRL moieties of PRL can be formed by covalent and non-covalent binding of 
PRL monomers with other PRL monomers, binding proteins, and immunoglobulins. A 
PRL binding protein in human serum has been observed to bind to human PRL and growth 
hormone, producing larger protein aggregates of ~30-60 kDa (Kline and Clevenger, 2001). 
Immunoglobulins can also form complexes with PRL (Cavaco et al., 1995). These high 
molecular weight forms are often referred to as “big” or “big-big” PRL and can range from 
45 to over 100 kDa, respectively (Sinha, 1992). Research on larger PRL moieties has been 
extensively studied in human medicine in relation to a condition termed 
“macroprolactinemia,” as a form of hyperprolactinemia (Cavaco et al., 1995). 
Macroprolactin has been shown to be bioactive in vitro but not in vivo, indicating that larger 
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PRL forms cannot gain access to receptors as they may not be able to pass through the 
pituitary capillary bed (Andersen et al., 1982). Big PRL makes up ~15-30% of serum PRL 
while big-big forms range from 0-10% in humans (Suh and Frantz, 1974).  
Synthesis and secretion of prolactin 
The pituitary gland is made up of two main lobes, anterior and posterior. An 
intermediate lobe exists in most species, but is not present as a defined structure in humans 
(Larkin and Ansorge, 2017). The anterior lobe contains specialized cells called lactotrophs, 
that synthesize and secrete of PRL. The pituitary is formed with the expansion of Rathke’s 
pouch (Brinkmeier et al., 2009) at ~20 d of gestation in the rat (Fisher et al.,1977) and ~4 
wks in humans (Larkin and Ansorge, 2017). In cattle, development of the pituitary must 
occur prior to 60 d of gestation, as secretion of GH was observed at ~60 d of gestation 
while secretion of PRL was observed at 98 d of gestation (Kineman et al., 1992). 
  Earlier identification of pituitary cell types within the anterior lobe were named 
according to their staining properties by aldehyde-fuchsin which will stain lactotrophs 
(acidophils) orange, basophils will stain blue or green and chromophobes will not take up 
stain as readily as either acidophils or basophils (Halmi, 1950). With immune-
histochemistry and more advanced microscopy, populations of cell types were named 
according to what hormone each produce and secrete as well as their target organs 
(Kurosumi, 1968). Corticotropes, thyroropes, somatotropes, gonadotropes and lactotropes 
produce and secrete, adrenocorticotropin (ACTH), thyroid stimulating hormone (TSH), 
growth hormone (GH), leutinizing hormone (LH), follicle stimulating hormone (FSH), and 
PRL, respectively. However, there are exceptions for somatotrophs, with cell morphology 
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able to change under hormonal influence; an example being the change in somatotroph 
secretion during pregnancy (Goluboff et al., 1969). In the presence of estrogen, 
somatotropes are able to switch secretion from GH to PRL (Stratmann et al., 1974). 
Prolactin undergoes packaging in granules prior to release. Granules are formed in the 
Golgi apparatus, within the lamellae (Farquhar and Wellings 1957) and range in size from 
approximately 200 nm to the largest at around 500 nm cattle (Tesar et al., 1969). Granule 
size varies in response to varying physiological status and need. Granules reach maximum 
size when storage of hormones is high and they become more localized at the cell 
membrane in anticipation for exocytosis. When in a state of higher synthesis, the granules 
are localized in the Golgi (Farquhar and Rinehart, 1954). Experiments to assess dynamic 
state of lactotrophs in relation to PRL heterogeneity observed that hyperstimulated 
lactotrophs bypass packaging and polymerization of PRL when the need for exocytosis 
was greater, as in the presence of a secretogogue, whereas interruption of the stimulation 
caused lactotrophs to build up secretory granules due to lack of exocytosis (Torres and 
Aoki, 1985).  
There are four types of granules categorized by size and positioning within the 
lactotroph. Studied in rats, granules 100-200 nm in size are considered type I granules, 
found within the Golgi. Slightly larger granules, type II, are also within the golgi or 
associated with the Golgi but form aggregates with other granules. Type III and Type IV 
granules are much larger and more irregular shaped then the smaller Type I round granules. 
Type IV granules can get to approximately 900 nm in size (Farquhar, Reid and Daniell, 
1978). Through a pulse-chase experiment, in which pituitary cells were “pulsed” with [3H] 
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leucine to label PRL proteins followed by “chased” with unlabeled medium it was 
concluded that the path PRL takes through intracellular processing and then onto packaging 
within secretory granules is through the endoplasmic reticulum (ER) and then the Golgi in 
which immature granules form and then mature granules move out to the cytoplasm for 
exocytosis. Localization of granules in the ER occurred immediately after cells were 
pulsed. Within 5 minutes all labeled granules were associated with the Golgi. These labels 
then showed a progression from Type I all the way to Type IV granules for packaging 
within 15 minutes of transport from the Golgi (Farquhar, Reid and Daniell, 1978). 
Monomeric PRL was observed localized to organelles while big PRL moieties were 
observed aggregated and stored in granules (Torres and Aoki, 1987).  
Secretion of PRL has been shown to be dependent on calcium influx (Zorec et al., 1991; 
Ratovondrahona et al., 1998). The activation of phospholipase C (PLC) is followed by 
hydrolysis of membrane bound phosphatidylinositol 4,5-bisphosphate (PIP2) for formation 
of inositol phosphates and diacylglycerol (DAG). Protein kinase C (PKC) is recruited and 
activated by DAG. Inositol phosphate 3 binds its receptor in the endoplasmic reticulum 
(ER) to increase mobilization of calcium from the ER. Phospholipase 3 phosphorylates 
voltage-gated calcium channels to facilitate increased influx of intracellular calcium for 
exocytosis of PRL (Fomina and Levitan, 1995).  
There is evidence that secretion of PRL varies in response to physiological status. 
The most classic example originates from the early pigeon crop assays. Prolactin, facilitates 
brooding in pigeons, further an increase in mitotic activity (Lahr and Riddle, 1938) and 
differentiation (Dumont, 1965) of crop epithelial cells is observed for the production of 
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crop milk to feed young (Lahr and Riddle, 1938). Heightened serum PRL concentrations 
are also observed due to longer photoperiod (Pelletier, 1973; Bourne and Tucker, 1975; 
Peters and Tucker, 1978; Kennaway et al., 1983; Griffith and Minton, 1992). For example, 
rodents experience a decrease in synthesis and secretion of PRL during testicular 
regression, occurring as a result of a shorter photoperiod (Filippa and Mohamed, 2010). 
Increased stress has also been shown to increase levels of prolactin (Angelier and Chastel, 
2005; Dorshkind and Horseman, 2000). 
Other sources of prolactin 
Aside from the pituitary, PRL is synthesized in other tissues. Most research on extra-
pituitary sources of PRL is in females, as reviewed extensively by Ben-Jonathan (1996). 
Most recently, PRL has been reported in seminal fluid of humans and cattle (Sheth et al., 
1975; Pratt et al., 2014). Further research to determine synthesis of PRL in male 
reproductive tissues is needed to uncover the mechanism of impact of PRL on male 
reproductive physiology. Prolactin’s presence in seminal fluid implicates involvement in 
semen quality for possibly autocrine and paracrine actions of PRL. Further, the possibility 
also exists that endocrine effects could be exerted by PRL from the pituitary on male 
reproductive tissues such as the testis and accessory glands, impacting semen quality or 
fertility. Investigation of the presence of PRLR in these male reproductive tissues, and 
further, assays to asses binding of PRLR locally could help to elucidate how PRL exerts 
effects on male reproductive physiology.  
Regulation 
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 Gene expression of PRL is regulated through a proximal promoter region spanning 
40 to 250 bp upstream of a canonical TATA box in the proximal region of the PRL gene 
(Peers et al., 1990). Extra-pituitary sources of PRL are regulated through another distal 
regulatory element 5.8 kilobases upstream of Exon 1a (Berwaer et al., 1994). This distal 
promoter controls extra-pituitary prolactin expression in primates, but is not present in 
rodents (Christensen et al., 2013). Further modulation occurs by regulatory elements 
located within the proximal promoter (Peers et al., 1990), containing pit-1 binding sites, a 
transcription factor known to control prolactin transcription (Elsholtz et al., 1991; Lew et 
al., 1994). Moreover, two more regulatory elements are located even more distally at 
approximately 1750 bp and another at approximately 5000 bp upstream of the promoter 
region (Peers et al., 1990).  
Pituitary PRL is under tonic inhibition by hypothalamic sources of dopamine (Ben-
Jonathan and Hnasko, 2001). Dopamine suppresses PRL synthesis through binding to the 
dopamine Type-2 receptor (DRD2), a G-protein coupled receptor (Baertschi et al., 1992; 
Lledo et al., 1992). Binding initiates a conformational change that will prompt an exchange 
of GDP for GTP on the alpha subunit of the coupled G-inhibitory protein, resulting in 
dissociation of the alpha subunit from the beta and gamma subunits. The dissociation 
allows for the subunits to interact with other proteins, receptors, and ion channels to 
facilitate inhibition of PRL synthesis and secretion. In the case of interaction with ion 
channels, coupling is facilitated by the GTP-binding protein beta and gamma subunits 
interaction with gated inward-rectifying potassium channels, increasing potassium 
conductance and causing calcium channels to close resulting in decreased intracellular 
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calcium concentration (Pillai et al., 1998). The coupled G-inhibitory protein alpha subunit 
can also interact with and inhibit adenylyl cyclase, preventing the conversion of ATP to 
second messenger cAMP needed for activation of protein kinase A (PKA) (Ben-Jonathan 
and Hnasko, 2001; Lledo et al., 1992; Enjalbert and Bockaert, 1983) (Figure 1.1). Without 
activation, PKA remains in a deactivated state and does not phosphorylate cAMP response 
element binding proteins (CREB). As a result, CREB is unable to bind to cAMP response 
element (CRE) domains and subsequently bind cAMP binding protein. Consequently, 
binding of CBP to facilitate activation of pit-1 for stimulation of PRL transcription will not 
occur (Kapiloff et al., 1991). The alpha subunit can also interact with and inhibit PLC, 
inhibiting the subsequent hydrolysis of PIP2, formation of inositol phosphates and DAG 
proteins. Activation of PKC does not occur and Inositol phosphate 3 cannot bind its 
receptor in the ER for mobilization of calcium necessary for exocytosis of PRL (Figure 
1.2) (Fomina and Levitan, 1995).  
Dopamine supply to lactotrophs for regulation of PRL originates from neurons located 
in the arcuate nucleus that extend to the median eminence where dopamine is transported 
through the portal blood system terminating in the anterior pituitary (Bjorklund et al., 1974; 
Fuxe, 1964). The nuclei are classified according to Andén et al. (1966) and are indicated 
by A11-A15. The perikarya responsible for dopamine transport, specifically to the anterior 
pituitary, are within the A12 region of the arcuate nucleus, called tuberoinfundibular 
neurons (TIDA). Axons project into the median eminence where released dopamine is 
picked up by longer portal vessels that carry the supply of dopamine to the capillaries of 
the hypophysial portal vessels and directly to the anterior pituitary (Fuxe, 1963). Prolactin 
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receptors are located on dopaminergic neurons which allow prolactin to regulate its own 
secretion through a short feedback loop. Prolactin is proposed to feedback in this manner 
to effect mRNA abundance of TH, and therefore, the production of dopamine (Arbogast 
and Voogt, 1991). 
Less defined methods of dopaminergic inhibitory effects on PRL are through the 
Ras-Raf-MEK-ERK pathway. Suppression of ERK was diminished following mutation of 
DRD2 coupled G-inhibitory proteins. Specifically, Gao, but not Gai2 coupled to dopamine 
receptors suppresses ERK1 and ERK2 activation (Liu et al., 2002). This is inconsistent 
with research in glioma cells, indicating a stimulatory role for dopamine on ERK (Luo et 
al., 1997). Differences may be attributed to cell type as the suppression of ERK by 
dopamine seems to be unique to pituitary cells. Moreover, abundance of isoform, long or 
short DRD2, may differ between cell types. Transgenic mice produced with overexpression 
of the short DRD2 isoform in lactotrophs, increases induction of the Ras-Raf-MEK-ERK 
pathway and consequently, pituitary hypoplasia and decreased serum PRL concentrations. 
Overexpression of DRD2 long isoform does not induce activation of the ERK pathway and 
therefore, PRL serum concentrations are higher in DRD2 long isoform overexpressed mice 
(Laccarino et al., 2002). 
Function in male reproduction 
The role of PRL is not well understood in male reproductive physiology. Most of 
the research regarding PRL and its effects on male physiology were performed in knockout 
mouse models. However, research is conflicting and has not yet provided a clear and 
consistent role. Prolactin ablation experiments showed fertile PRL deficient males when 
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they were mated with heterozygous females (Horseman et al., 1997) while experiments 
utilizing ablation of the PRLR in mice report none or only a slight decrease in fertility 
(Binart et al., 2003; Ormandy C.J. et al., 1997). Moreover, most knockout experiments 
were conducted under optimal conditions with few females and adequate feed available, 
which does not compare to conditions that would occur naturally or in an agricultural 
setting. Further, differences in species exist with PRL not found in rodent testis 
(Christensen H.R. et al., 2013).  
Consumption of a forage containing a naturally ocurring dopamine agonist, ergot 
alkaloids,  decreases serum PRL concentrations and negativley impacts fertility in cattle 
(Schuenemann at al., 2005). In human males, fluctuations in PRL concentrations have also 
been observed to affect male reproductive function with hyperprolactinemia patients 
associated with a high instance of infertility (Segal et al., 1976). Findings are contradictory 
with the ablation of the PRL gene in mice resulting in no differences in fertility measured 
by number of live pups per litter and rate of pregnancy in male PRL knockout mice mated 
to normal female mice (Horseman et al., 1997; Stegar et al., 1998). Studies from our 
laboratory, performed across three years, utilized fresh extended semen from bulls exposed 
to a dopamine agonist or not for artificial insemination to primi- and multiparous cows. 
Serum PRL concentrations were determined in the second study by radioimmunoassay. 
Results indicated lower serum PRL concentrations due to exposure to a dopamine agonist; 
however, pregnancy rates 35 d post-timed artificial insemination in the second study did 
not differ in cows artificially inseminated with fresh extended semen from bulls with 
decreased PRL serum concentrations. (Burnett et al., 2018).   
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Prolactin has been implicated in a role for stimulation of testicular responsiveness. 
The mechanism in which PRL exerts affects are not well understood (Bartke et al., 1977; 
Sanford and Baker, 2010). Hamsters treated with a PRL anterior pituitary transplant more 
rapidly experience testicular recrudescence in the presence of human chorionic 
gonadotropin, while hamsters treated with a dopamine agonist, bromocriptine, displayed 
delayed testicular recrudescence in the Spring (Bartke et al., 1980). Effects of PRL could 
be exerted by effects on steroidogenesis, as PRL-deficient mice treated with exogenous 
ovine PRL or an ectopic homograft exhibit elevated testosterone in response to treatment 
of human chorionic gonadotropin in vitro (Bartke et al., 1977). However, changes in 
testosterone due to serum PRL concentrations has not been reported across species with 
studies indicating no change in testosterone levels in cattle (Smith et al., 1973; Pratt et al., 
2015). Leydig cells do possess high affinity binding sites for PRL (Ka = 8.7 nM) (Barkey 
et al., 1987), but in cell culture performed with Percoll gradient isolated rat Leydig cells in 
a serum-free medium, a dose-dependent response to treatment of ovine PRL was observed 
to exacerbate inhibitory effects of PRL on testosterone secretion in 3 d culture (Barkey et 
al., 1987).  Testosterone secretion by Leydig cells in response to treatment with human 
chorionic gonadotropin was inhibited maximally at 100 ng/mL and minimally at the 
highest does of 500 ng/mL. This same inhibition was not observed short term in culture for 
4 h. (Barkey et al., 1987).   
Effects on steroidogenesis by PRL may also be due to effects on LH receptors. 
Evidence for maintenance of LH receptors on Leydig cells by PRL is observed in rams 
treated with a dopamine agonist, bromocriptine (Sanford and Baker, 2010). A tendency 
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was observed for 25-30 % decreased LH receptor abundance in testis during testicular 
regression in rams treated with a dopamine agonist. In response to treatment with LH, rams 
treated with bromocriptine displayed a 20 % decrease in testosterone secreted by the testis 
(Sanford and Baker, 2010). If PRL does play a role in augmentation of testosterone, there 
is likely more involved than solely maintenance of LH receptors as the effects observed in 
rams. The reduction in LH receptors in the testis were observed during testicular regression, 
when testosterone is much lower to begin with (Sanford and baker, 2010). In contrast to 
rams, LH receptor availability on Leydig cells is increased with treatment of exogenous 
PRL in hypophysectomized rats but did not alter binding affinity (Purvis et al., 1979). 
Prolactin was observed to act synergistically with LH to stimulate steroidogenesis in the 
testis as measured by the dose response of isolated Leydig cells to human chorionic 
gonadotropin in rats; however, like in rams, testosterone levels were unaltered by treatment 
of exogenous PRL (Purvis et al., 1979). Taken together, findings on PRL role in 
steroidogenesis is unclear and warrants further investigation. 
Overabundance of PRL, or hyperprolactinemia, is associated with hyperplasia of 
the prostate (Wennbo et al., 1997). Moreover, PRL has been implicated in cancer of the 
prostate (Mee et al., 1984; Costello and Franklin, 1994) attributed to PRL enhancement of 
testosterone levels, as testosterone is the main regulator of the prostate (George and 
Peterson, 1988). Prolactin has been shown, in conjunction with testosterone implants in 
mice, to increase the level of androgen receptor availability in the prostate, specifically in 
the lateral lobe, allowing for increased responsiveness to testosterone (Prins, 1987). 
However, later studies in human prostate cancer cells, confirmed both PRL and 
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testosterone function to enhance zinc uptake, with increasing zinc corresponding to 
prostate malignancy (Costello et al., 1999). Results in both testis and prostate confirm a 
contradictory role for PRL on testosterone levels. However, research findings in the 
prostate indicate a synergistic role of both PRL and testosterone in trophic effects (Costello 
et al., 1999). However, experiments to elucidate the precise role or roles of PRL on 
steroidogenesis is warranted. 
Prolactin has been identified in seminal fluid of cattle and humans (Pratt et al., 
2014; Sheth et al., 1975). Prolactin’s role in semen quality is very unclear as there are 
differences in findings within the literature. In cattle consuming a forage containing a 
dopamine agonist, in which serum PRL concentrations are lowered, semen motility and 
morphology are negatively affected (Looper et al., 2009; Pratt et al., 2014). Moreover, 
hypoprolactinemia is highly associated with semen quality issues leading to infertility in 
human males (Gonzalez et al., 1989). Interestingly, semen from bulls exposed to a 
dopamine agonist exhibit decreased semen freezing potential. Post-thaw, semen exhibits 
decreased motility as assessed by sperm-quality analysis. Sperm cells from semen collected 
from these bulls exhibited an overall lower percentage of normal morphology compared to 
those bulls not exposed to a dopamine agonist suggesting a role for PRL in sperm structure 
for why motility is so affected post-thaw. Semen utilized to test freezing was above 
acceptable sperm morphology percentage (75 %) at the start of freezing and total sperm 
number was unchanged post-thaw indicating the effect was not due to concentration or 
initial quality pre-freezing (Pratt et al., 2015). Others have reported no change in semen 
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quality as a result of decreased serum PRL concentrations (Schuenemann et al., 2005; 
Stowe et al., 2013).  
There is evidence that PRL may indirectly play a role in spermatogenesis by 
increasing lipids needed for the spermatogenic processes (Gunasekar et al., 1991). 
Monkeys, immature and mature were injected with 1mg/kg body weight of either ovine 
PRL or bromocriptine (a dopamine agonist) twice a day for 10 days. Total cellular lipids 
increased in germ cells, ~15 mg/g to 25 mg/g in mature monkeys and ~12 mg/g to ~20m 
mg/g in immature monkeys (Gunasekar et al., 1991). A decrease in mg/g lipids was 
observed in Leydig cells of mature monkeys but not in immature monkeys treated with 
PRL at 40 mg/g in untreated monkeys compared to 30 mg/g in PRL treated monkeys 
(Gunasekar et al., 1991). Prolactin treatment showed the same effect on cholesterol levels 
in Leydig cells, with a decrease in cholecterol in Leydig cells of PRL treated mature 
monkeys compared to untreated controls (1 mg/g; 5 mg/g). Taken together, age could play 
a role in the effect of PRL on lipid accumulation in Leydig cells and suggests that there 
could be further effecs on steroidogenesis through Leydig cell production of testosterone 
(Gunasekar et al., 1991).  
Prolactin’s role in semen quality is further supported by a restriction in maturation 
of spermatocytes to spermatids in rats following a decrease in PRL concentration (Nag et 
al., 1981). However, exposure to a dopamine agonist had no effect on semen quality in 
yearling bulls (Burnett et al., 2018). Further, when bulls were monitored through two full 
spermatogenic cycles, bulls grazing a dopaminergic agonist exhibited no differences in 
semen quality as assessed by computer assisted semen analysis (CASA), a computer 
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program that utilizes an algorithm to track motility parameters of sperm cells as they move 
on recorded short video clips (Stowe et al., 2013).  Given all the conflicting findings, at 
present, PRL’s role in semen quality has not been clearly defined.   
Prolactin Receptor 
Structure 
The Class 1 cytokine receptor family includes receptors for PRL and growth 
hormone (GH) (Goffin and Kelly, 1997). The general structure of PRLR protein consists 
of a single chain protein with a single transmembrane domain, a cytoplasmic domain, and 
an extracellular region. The receptors bind in a 2:1 ratio, with 2 receptors binding to one 
PRL protein (Bole-Feysot et al., 1998). The extracellular domain of PRLR consists of two 
regions, the amino-terminal and membrane-proximal regions. The receptors contain two 
sets of conserved disulfide-linked cysteines located in the amino-terminal portion (Boutin 
et al., 1988, 1989). Within the membrane proximal region, there is a conserved region 
assigned the ‘WS motif’ (WSXWS) that facilitates ligand binding (Rozakis-Adcock and 
Kelly, 1992). Radiolabeled ligand binding assays performed with a WSXWS motif mutated 
PRLR (all five residues mutated with alanine) resulted in decreased binding affinity as 
measured by Kd, 0.29 ± 0.04 nM for wild type unmutated control, and 6.76 ± 1.4 nM for 
the mutated receptor, (Rozakis-Adcock and Kelly, 1992). Similar findings have been 
implicated in other cytokine receptor types finding the motif functions for assistance in 
folding of secondary protein structure in erythropoietin receptors (Hilton et al., 1996). A 
decrease or complete loss of erythropoietin receptor availability at the cell membrane has 
been observed due to reduced migration from the endoplasmic reticulum consequence of 
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mutation of the serine and tryptophan residues in the WS motif effects on secondary 
structure (Hilton et al., 1996). Similar results have been reported with mutation of the 
tryptophan residues in the same receptor resulting in impaired or abolished ligand 
internalization and binding (Quelle et al., 1992). The importance of tryptophan residues 
adjacent to the serine residues in the WSXWS motif may be due to polarity of the sequence 
and the ability of the tryptophan residues to provide the necessary scaffolding for proper 
support of the serine polar residues and therefore proper hydrogen binding to beta sheets 
(Quelle et al., 1992). This would agree with observations by Bazan (1990) who proposed 
the WSXWS motif was located on a loop connecting the amino-terminal and membrane 
proximal regions of the extracellular domain in which proper folding would not be 
permitted with substitutions of the outer tryptophan residues do to its location on a hinged 
region. 
The intracellular portion of PRLR contains two regions, deemed Box 1 and 2, that 
are conserved across all isoforms of the PRLR with the exception of Box 2 in some 
isoforms of the receptor with shorter cytoplasmic lengths (Goffin et al., 1997). Box 1 is a 
proline rich region that has been shown to be essential for association of JAK2 with PRLR 
and further, activation (Tanner et al., 1995). Experiments in human kidney fibroblasts 
transfected with a pRc/CMV expression vector containing the PRLR cDNA encoding 
various mutated prolines within Box 1 indicate that association of Janus Kinase 2 (JAK2) 
to the PRLR requires the last proline in Box 1 (residue 250). When this proline is mutated, 
JAK2 does not associate with the PRLR and subsequent phosphorylation of signal 
transducer and activators of transcription 5 (STAT5) cannot occur for facilitation of PRL 
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transcriptional activity (Pezet et al., 1997). It is not surprising that Box 1 plays such an 
important role in PRLR signaling since the sequence is conserved across both short and 
long PRLR across species; however, Box 1 alone is not sufficient to permit PRL signal 
transduction as two other regions, one between Box 1 and 2 and the other in the carboxyl 
terminal have been shown as necessary for transcriptional activity of the b casein promoter, 
a promoter who’s activation is dependent on PRL (Lebrun et al., 1995). 
The PRLR gene is located on Chromosome 2 in rats, Chromosome 5 in humans 
(Arden et al., 1990), Chromosome 13 in mice (Jackson et al., 1988), and Chromosome 20 
in cattle (Hayes et al., 1996). Complimentary DNA sequences have been characterized in 
a number of species and encode for PRLR proteins of varying cytoplasmic domain length 
(Bignon et al., 1997; Anthony et al., 1995; Shirota et al., 1990).  Characterization of a 
cDNA clone performed in rat liver encoded for a short PRLR protein predicted to be 291 
amino acids in length with an average mass of ~40 kDa (Boutin et al., 1988). The cDNA 
encoded a predicted transmembrane domain of 25 amino acids in length and the 
extracellular domain was ~210 amino acids in length. A ~55 amino acid cytoplasmic 
domain was observed for the short PRLR protein in rat liver (Boutin et al.,1988). A longer 
PRLR protein was characterized from a cDNA clone derived from rat ovary that encoded 
for a PRLR protein with a cytoplasmic domain ~300 bp longer than the previously 
identified short PRLR isoform in rat liver with a molecular mass of 80 kDa (Shirota et al., 
1990). An intermediate isoform has been identified in the rat lymphoma Nb2 cell line and 
in a human breast cancer cell line (Ali et al., 1991; Kline et al., 1999). The intermediate 
isoform lacks ~200 amino acids in the cytoplasmic domain with a molecular mass just shy 
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of the long receptor at 60 kDa in rats (Ali et al., 1991). In humans the intermediate isoform 
is homologous to the long PRLR up to nucleotide position 1582 in which a 573-nucleotide 
deletion was found, causing a frame shift that resulted in an early stop codon in the carboxyl 
terminal (Kline et al., 1999). Similarly, multiple PRLR isoforms have been identified in 
mice, however mice possess three short and one long isoform, identified by characterizing 
cDNA clones generated from the liver (Davis and Linzer, 1989). In humans, a long PRLR 
isoform has also been cloned from the liver (Boutin et al., 1989), an intermediate form 
from a breast cancer cell line (Kline et al., 1999), multiple short forms, and a soluble 
binding protein (lacking the entire cytoplasmic portion of the receptor) have been identified 
(Hu et al., 2001; Trott et al., 2003). The intermediate isoform has similar binding affinity 
and signaling properties to long PRLR (Kline et al., 1999).  
One long and one short PRLR have been identified in bovine fetal and placental 
tissues (Scott et al., 1992; Schuler et al., 1997). The long receptor was characterized from 
endometrial cDNA and the preprotein was predicted to be 557 amino acids in length (Scott 
et al., 1992). The long bovine PRLR differs in length from human and rats due to an extra 
stop codon in the 3’ region encoding the cytoplasmic domain (Scott et al., 1992). 
Messenger RNA expression of short variants of the mouse PRLR have been observed to 
vary throughout pregnancy in the ovary. One short PRLR variant was differentially 
expressed in atretic follicles, corpora lutea and interstitial cells suggesting a role in 
follicular atresia (Clarke and Linzer, 1993). Findings for a specialized role of short PRLR 
in the mouse placed emphasis on possibilities of these PRLR isoforms in other species. 
Shortly after, one short and one long PRLR were isolated and characterized in ovine fetal 
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liver and adult ovaries (Anthony et al., 1995). Characterization of the second sequence 
revealed an almost identical cDNA sequence up until nucleotide 420 in which an extra 39 
base pairs were inserted. The cDNA encoded for a protein lacking the conserved box 2 
sequence due to a truncation in the cytoplasmic domain, encoding for the short ovine PRLR 
(Anthony et al., 1995). The primer sequences used to identify PRLR in sheep (Anthony et 
al., 1995) were then used for the identification of a short bovine PRLR variant that encoded 
a protein similar to that reported in sheep, with a truncated receptor at 227 amino acids in 
length containing no Box 2 sequence (Schuler et al., 1997). 
In ruminants, the short isoform of the PRLR is produced as a result of an extra 39 
bp sequence at residue 420, containing two alternative 3’ stop codons. Ruminants utilize 
an intron retention mechanism of alternative splicing that spans a single 5’ or two 3’ 
alternative sites on the extra 39 bp insert to produce a short or long receptor. Splicing 
patterns for PRLR are different in rodents which utilize excision or inclusion of three exons 
in the 3’ region to produce long and short PRLR, respectively. However, the end resulting 
protein is extremely similar across ruminants and rodents regardless of their splicing 
method (Bignon et al., 1997).  
Short isoforms of the PRLR serve as compensatory signaling if the loss of long 
PRLR occurs. This effect has been demonstrated by restoration of normal mammary gland 
development in mice through overexpression of short PRLR in mice heterozygous for the 
long PRLR (Binart et al., 2003). However, this is not what is observed in cattle. The long, 
but not short PRLR was able to promote gene expression when transfected into a bovine 
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endometrial stromal cell line indicating the specialized functionality of short PRLR in 
rodents is not the same in cattle (Schuler et al., 1997).   
Differences in functionality may be due to splicing out of tyrosine residues within 
the cytoplasmic domain. Shorter PRLR isoforms lack some if not all of these essential 
tyrosine residues depending on where splicing occurs (Schuler et al., 1997). In cattle, the 
long PRLR is slightly truncated due to an extra stop codon, resulting in the loss of a tyrosine 
residue thought to be important for STAT5 docking in rats; however, the slightly truncated 
receptor was still able to stimulate transcription (Schuler et al., 1997). The receptor’s ability 
to stimulate transcription indicates it may use other tyrosines for STAT docking and 
initiation of transcriptional activity. Importance of tyrosine residues have been evaluated 
with mutation experiments. Particularly tyrosine 580, results in depletion of STAT5 
activation and downstream gene expression. However, tyrosine 479 and 473 allow for 
retention of ~20 % activation when tyrosine 580 is mutated. (Pezet et al., 1997). 
Explanation of differences across species in ability to initiate signaling through short PRLR 
could also be due to heterodimerization. Short PRLR isoforms inhibit long PRLR thought 
heterodimerization. When the two receptors were co-expressed in human embryonic 
kidney fibroblast cells, activation by phosphorylation of JAK2 and the PRLR does not 
occur, therefore transcriptional activation is prevented (Perrot-Applanat et al., 1997). Such 
heterodimerization has also been reported in humans (Qazi et al., 2006).  
Expression and Function in the male 
Prolactin receptor mRNA has been reported in rat interstitial cells, Leydig and 
Sertoli cells, and sperm cells (Hondo et al., 1995). In situ hybridization in the rat indicates 
 23 
signal for PRLR in Leydig and endothelial cells within interstitial space in the testis as well 
as staining in the epithelial layer of the seminiferous tubules (Hondo et al., 1995). Similar 
localization was confirmed in rams and red deer with in situ hybridization revealing signal 
for PRLR in the seminiferous tubules, specifically Leydig and developing sperm cells, 
interstitial space, and the epithelial layer of the epididymis of the red deer. (Jabbour and 
Lincoln, 1999).  More recently, PRLR gene expression has been reported in bull and human 
testis (Hair et al., 2002; Pratt et al 2014). Immunohistochemistry confirmed localization of 
PRLR in Leydig cells and the interstitial space in the seminiferous lumen in the testis in 
humans and bulls, respectively (Hair et al., 2002; Pratt et al., 2014). 
Prolactin receptor gene expression in the interstitial space and in Leydig cells 
suggests a possible role for PRL on steroidogenesis, as Leydig cells produce testosterone. 
In vitro studies in the rat testis indicate that circulating serum PRL concentrations impact 
LH receptors (Aragona et al., 1977). However, in vivo experiments in hamsters indicate 
PRL alone does not modulate steroidogenesis, as other factors such as FSH and LH are 
needed to gain full enhancement of steroidogenesis in the testis (Klemcke et al., 1990).  
Prolactin receptor expression in developing sperm cells suggests a direct role for 
PRL in spermatogenesis. Evidence for effects on germ cells has been reported. 
Hypophysectomized rats treated with exogenous PRL display an increase in number of 
primary spermatocytes as well as overall number of germ cells (Dombrowicz et al.,1992); 
however, sperm concentration does not seem to be altered in patients with 
hyperprolactinemia (Merino et al., 1997) but increased serum PRL has been associated 
with reduced semen motility (Gonzales et al., 1989). Studies using PRLR ablation in mice 
 24 
indicate that PRL does not play a direct role in spermatogenesis or steroidogenesis, as 
histology of the testis was unaffected and there was no change in testosterone levels (Binart 
et al., 2003). Effects may differ due to species with rodents possessing possible 
compensatory mechanisms.  
Mouse PRLR ablation experiments report that the loss of PRLR slightly impacts 
male fertility (Ormandy et al., 1997). However, later experiments utilizing the same PRLR 
knockout model, found that there was no change in male fertility due to PRLR knockout 
(Binart et al., 2003). Male fertility was assessed by mating a male mouse with complete 
knockout of the PRLR (PRLR(-/-)) with a heterozygous female PRLR(-/+). Males were 
considered fully fertile if they produced pregnancies after the first vaginal plug observed, 
and considered partially or completely infertile if they took several times to produce 
pregnancies after the observation of a vaginal plug or they never produced pregnancies, 
respectively (Binart et al., 2003). Knockout mouse models therefore predict that there is no 
association of PRL on overall fertility in males. However, across species this differs with 
hyperprolactinemic human males reported as infertile (Segal et al., 1976) and cattle with 
decreased serum PRL concentrations displaying detrimental effects to semen motility and 
morphology (Looper et al., 2009; Pratt et al., 2014).  
Overall, research in PRLR(-/-) models differ in observations within and across 
laboratories on the role of PRL in spermatogenesis and steroidogenesis. Results also vary 
in in vitro models versus in vivo animal studies on the role of PRL in steroidogenesis. Given 
the severity of differences, further exploration of the PRLR and PRL impact on male 
reproductive physiology are intriguing. 
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JAK/STAT Pathway 
The JAK/STAT pathway is activated by cytokines including PRL (Ihle and Kerr, 
1995) (Figure 1.3). Prolactin binds to its receptors possessing two binding sites in which 
each single chian protein receptor binds to one of the two sites on the PRL protein. 
Dimerization and ligand binding prompt a conformational change to occur in the 
cytoplasmic region of the receptor (Ihle and Kerr, 1995; Gertler et al., 1996). The 
conformational change activates the the constitutively associated JAK2 to be 
transphosphorylated (Rui H. et al., 1992). Activation of JAK2 results in phosphorylation 
of tyrosine residues on the PRLR allowing STAT5 molecules to bind to these tyrosine sites 
and undergo phosphorylation by JAK2 (Gouilleux et al., 1994; Kisseleva et al., 2002). The 
STAT5 molecules then disassociate from the receptor and dimerize, followed by 
translocation to the nucleus to effect transcriptional activity by binding to enhancer regions, 
such as gamma interferon activated sites (GAS) (Ihle, 1996).  
Four different JAKs have been identified, JAK 1, JAK 2, JAK 3, and TYK 2 with 
all except JAK 3 expressed ubiquitously (Kisseleva et al., 2002). Janus kinases are 120-
130 kDa proteins, ~1150 amino acids in length and are structurally categorized by 7 
domains (JH1-JH7) (Kisseleva et al., 2002). The tyrosine kinase domain (JH1) contains all 
the conserved tyrosine residues that are responsible for the conformational change to the 
PRLR proceeding phosphorylation (Hubbard, 2018). Phosphorylation of JAK2 occurs in 
tyrosine residues Tyr1007 and 1008 (Hubbard, 2018) located in the activation loop to 
facilitate activation of JAK2. Phosphorylation of Tyr 813 has been shown to be a main site 
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for phosphorylation to facilitate binding the Src homology 2 (SH2) domain in STAT5 to 
JAK2 (Kurzer et al., 2004). The N-terminal domain (JH3-JH7) has been implicated in 
binding specificity for cytokine receptors (Zhao et al., 1995) and is the least conserved in 
family members of the JAKs (Kisseleva et al., 2002). However, not much else is known 
about its function. The pseudokinase domain (JH2) lacks catalytic activity (Velazquez et 
al., 1995). Until recently, not much was known about the JH2 domain or its function. The 
JH2 domain functions to regulate JAK activation as observed by deletion of the JH2 
domain resulting in an increase in tyrosine phosphorylation of both JAK2 and STAT5 
(Saharinen et al., 2003). Further, two residues have been implicated in this negative 
regulation through mutation of the pseudokinase domain, (Ser 523 and Tyr 570) 
(Ungureanu et al., 2011). Phosphorylation of Ser 523 in the JH2 domain is the initial step 
of autophosphorylation of JAK2, followed by Tyr 570 (Ungureanu et al., 2011). 
There are seven identified STATs, approximately 750-850 amino acids in length at 
approximately 95 kDa. All STAT proteins share six conserved domains with the amino-
terminal portion of STATs has been shown to facilitate DNA-binding (Vinkemeier et al., 
1998). Structural characterization studies indicate that the N-terminal domain is made up 
of a folded dimerized structure in which the conformation permits binding to DNA 
elements (Vinkemeier et al., 1996). The first ~100 amino acids of the amino-terminal 
specifically, have also been shown to facilitate translocation of STAT dimers to the nucleus 
and after translocation, deactivation (Strehlow and Schindler, 1998). These first 100 amino 
acids are highly conserved among the STAT family, however, when chimeric STAT 
proteins were produced, the dimer was unable to translocate and deactivate, indicating that 
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the N-terminal domain is involved in more than was originally thought (Horvath et al., 
1995). The DNA binding domain favors a TTC(T/C)N(G/A)GAA GAS sequence  
corresponding to three conserved amino acids phenylalanine, glutamine, and glutamic acid 
for binding of STAT homodimers to DNA (Soldaini et al., 2000). The specific site of 
interaction occurs through the DNA-binding domain, specifically residues 470-474, that 
are inserted into the major groove of DNA (Soldaini et al., 2000) The coiled-coil domain 
directly proceeding the N-terminal domain, has been shown to facilitate nuclear 
translocation of STATs, sequestration to the receptor, as well as dimerization (Zhang et al., 
2000). These functions are all tyrosine phosphorylation dependent and deletions of 5’ 
coiled coil domain areas result in a loss of these functions due to a loss of phosphorylation 
when assessed in STAT3 function (Zhang et al., 2000). The SH2 domain plays a role in 
several functions, essential for STAT recruitment to the receptor by docking on 
phosphorylated tyrosine residues, dimerization that occurs prior to translocation to the 
nucleus, and associations with JAK for subsequent activation (Kisseleva et al., 2002). 
Ability of the SH2 domain to facilitate these actions occurs through recognition of specific 
sequences. The SH2 domain of STAT5 specifically recognizes Tyr, Leu, Asp, Pro, Thr 
motif for PRL receptor signaling (Lebrun et al., 1995).  
Ras/Raf/MEK/ERK signaling pathway 
 Aside from activation of the JAK-STAT pathway, mitogen-activated protein kinase 
(MAPK) pathways can also be activated through PRLR signaling. Adaptor proteins, src 
homology 2 domain containing protein (Shc), growth factor receptor-bound protein 2 
(Grb2), and son of sevenless (SOS) anchor to the phosphorylated tyrosine residue on the 
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PRLR to bridge the JAK-STAT signaling pathway to the Ras/Raf/MEK/ERK cascade (Das 
and Vonderhaar, 1996). Son of sevenless is a guanine nucleotide exchange factor that 
activates Ras, a small GTPase, through exchange of coupled GDP for GTP. Ras then 
phosphorylates Raf, a protein kinase related to an oncogene, followed by phosphorylation 
of MEK1/2 and ERK1/2 (extracellular signal regulated kinase). ERK1/2 then translocate 
to the nucleus to activate transcription factors such as (E26 transformation-specific) ETS 
factors (Bole-Feysot C. et al., 1998; Booth and Gutierrez-Hartman 2015; Clevenger et al., 
1998) (Figure 1.3). A Thr38 residue in ETS-1 is essential for the activation of ETS-1 by 
Ras (Yang et al., 1996). Transformation-specific factor E-26 and pit-1, the necessary 
homeodomain for the transcriptional activation of the prolactin gene (Ryan and Rosenfeld, 
1997), interact on the DNA to increase PRL promoter activity (Wasylyk B. et al., 1998).  
Dopamine 
Biosynthesis, storage, and exocytosis 
Dopamine synthesis occurs in the brain and in the kidneys (Soares Da Silva et al., 
1992; Ben-Jonathan and Hnasko, 2001). In the brain there are four major neuronal systems 
dopamine can be produced by; the mesocortical, tuberoinfundibular, mesolimbic, and 
nigro-striatal systems. Dopamine in hypophyseal blood was originally detected in rats by 
collection of portal blood from female rats in various stages of cyclicity, and in male rats 
either castrated or intact; detection of dopamine by radioenzymatic assay (Ben-Jonathan et 
al., 1977; Plotsky et al., 1978). The source of dopamine to hypophyseal blood was proposed 
to come from tuberoinfundibular (TIDA) neurons, with axons originating in the arcuate 
nucleus and terminating in the median eminence, releasing dopamine at the hypophysial 
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capillary bed (Smelik and Van Maanen, 1968). The capillary loops are connected to long 
portal vessels that carry released dopamine to the anterior pituitary (Smelik and Van 
Maanen, 1968). Tuberohypophyseal (THDA) neurons were later suggested as contributors 
of dopamine to the anterior pituitary when experiments utilizing posterior lobectomy 
resulted in elevation in serum PRL. The THDA neurons project axons from the 
periventricular nucleus to the posterior pituitary to supply dopamine to the anterior 
pituitary by transport through the small vascular networks connecting the posterior 
pituitary to the anterior lobe (Murai et al.,1986).  
  Dopamine is in the class of neurotransmitters called catecholamines. Dopamine, as 
with all catecholamines, have structurally defining features such as a catechol group, 
consisting of a benzol ring with two hydroxyl side chains and a single amine group 
(Nagatsu et al., 1964). Like all catecholamines, the synthesis of dopamine starts with 
tyrosine (Nagatsu et al., 1964). Tyrosine is readily available in the diet but can be produced 
by the hydroxylation of phenylalanine by phenylalanine hydroxylase in the liver (Moss and 
Schoenheimer, 1940). In dopaminergic neurons, tyrosine is hydroxylated to produce 
dihydroxyphenylalanine (DOPA) by the enzyme tyrosine hydroxylase (TH), with TH 
serving as the rate limiting step in dopamine synthesis. Further, DOPA is converted to 
dopamine by the enzyme, L-amino acid decarboxylase (Nagatsu et al., 1964).  
Tyrosine hydroxylase is structurally unique from other aromatic acid hydroxylases, 
as it contains an extra four serine residues in its R-domain (Campbell et al., 1986). 
Dopamine exerts negative feedback on TH activity, dependent on the need for 
neurotransmitter synthesis (Daubner et al., 2011). Phosphorylation of Ser40 primarily by 
 30 
PKA, results in activation of TH (Lovenberg et al., 1975) due to a conformational change 
that decreases affinity of dopamine for TH (Flatmark and Stevens, 1999). Inhibition of TH 
activation by dopamine is facilitated by competitive binding of dopamine and TH cofactor, 
tetrahydrobiopterin, for binding of the active site in the N-terminal region (Gordon et al., 
2008). Phosphorylation of Ser40 results in a 300-fold reduction in dopamine affinity for 
binding TH (Daubner et al., 1992; Ramsey et al., 1998). Deactivation of TH occurs with 
dephosphorylation by phosphatase PP2A (Saraf et al., 2010). Prolactin and TH participate 
in a short feedback loop for regulation of TH transcriptional activity. Increased signaling 
of PRL through the PRLR promotes increased TH mRNA, specifically in the hypothalamus 
regions in rats resulting in increased conversion of TH to L-DOPA (Arbogast and Voogt, 
1991). Tuberoinfundibular neurons were later discovered to possess PRLR (Arbogast and 
Voogt, 1997). 
Dopamine is taken up into secretory vesicles by vesicular monoamine transporters 
(VMATs). After packaging into secretory vesicles, the vesicles are moved to the synaptic 
region for exocytosis (Nirenberg et al., 1996). Monoamine transporter cDNA has been 
characterized and is present in bovine adrenal medulla. The cDNA encodes for a protein 
517 amino acids in length with a molecular weight of ~56 kDa (Howell et al., 1994). 
Vesicular monoamine transporters are found in two isoforms, VMAT 1 and VMAT 2. The 
VMAT 2 serves as a specific marker for monoamine containing neurons in the brain 
(Nirenberg et al., 1996). Transport and packaging are dependent on an electrochemical 
gradient and pH. Hydrogen ions are released, two for each dopamine molecule taken up by 
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the transporter and low acidic pH allows for the packaging of dopamine into storage 
vesicles (Njus et al., 1986). 
Further regulation of dopamine is through post-translational regulation of VMAT2. 
Phosphorylation occurs at both the N-terminal and C-terminal ends of VMAT2, both 
eliciting a different response. Phosphorylation at the N-terminal is likely performed by 
PKC on serine residues 15 and 18 and is implicated in regulation of efflux away from the 
synapse. A reduction of monoamine sequestration to vesicles and efflux from the synapse 
in response to treatment with methamphetamine (to permit a high-efflux state) has been 
observed (Torres and Ruoho, 2014). N-linked glycosylation occurs on the C-terminal and 
between transmembrane 1 and 2 (Yao and Hersh, 2007). Both must be phosphorylated to 
permit VMAT2 vesicle packaging (Yao and Hersh, 2007) 
Release and Reuptake 
Exocytosis of dopamine at the synapse is controlled through a flickering fusion pore 
or “kiss and run” exocytosis. Dopamine is released in multiple flickering events per single 
exocytotic event. It is the number of flickering events that control overall release of 
dopamine as each flicker releases ~25% of vesicle stored dopamine allowing controlled 
release of only partial vesicle content for use of vesicles multiple times (Staal et al., 2004). 
Trigger of exocytotic events is controlled by calcium influx through sodium and calcium 
exchange at the synapse (Taglialatela et al., 1990). Rate of diffusion and distance to binding 
target of dopamine have also been observed to influence number of flickers occurring and 
how much dopamine is therefore released (Cragg et al., 2004).  
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Dopamine transporters (DATs) participate in reuptake of dopamine that is released 
from the synapse but does not bind to its target receptor thereafter (Giros and Caron, 1993). 
Dopamine transporter cDNA has been characterized and is present in bovine substantia 
nigra. The reported cDNA sequence was 2340 nucleotides in length and encoded for a 
predicted protein 693 amino acids in length with an approximate molecular weight of 70 
kDa; 80 kDa when glycosylated. The protein consists of 12 transmembrane domains and 
three N-linked glycosylation sites located in the larger extracellular loop (Usdin et al., 
1991).  
Due to TIDA neuron termination in the median eminence and transportation of 
dopamine through perivascular space, TIDA neurons were thought not to form true 
synapses and were agreed to lack a functional DAT reuptake system (Demarest and Moore, 
1979). Original experiments were performed using radioenzymatic assays to determine the 
ratio of total dopamine concentration to dopamine accumulation in the presence or absence 
of a reuptake inhibitor. Findings indicated that not much reuptake occurs in the median 
eminence where TIDA neurons release dopamine (Demarest and Moore, 1979). 
Immunohistochemical experiments allowed for the visualization of DAT transporter 
immunoreactivity, observed localized in the median eminence where TIDA neurons release 
dopamine (Revay et al., 1996) and further, found in the pituitary stalk by 
immunocytochemistry (Demaria et al., 2000). Suppression of PRL gene expression was 
observed in the anterior pituitary of rats treated with a DAT blocker for 7 d indicating that 
without the reuptake mechanism in the median eminence, increased levels of dopamine 
were being transported from the median eminence through portal blood, to the anterior 
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pituitary to suppress PRL expression (Demaria et al., 2000). The DAT transporters have 
been localized in both perisynaptic and extra-synaptic regions (Nirenberg et al., 1996). 
Extra-synaptic localization of DAT suggests a role in regulating already released 
dopamine. Even though TIDA neurons release dopamine as a neurohormone, regulation 
by DAT is still possible after dopamine diffuses away from the synaptic region. After 
reuptake by DAT, dopamine is degraded through oxidation by monoamine oxidase or 
repackaged into a secretory vesicle (Nirenberg et al., 1996).  
Dopamine receptors largely regulate DAT function through increasing or 
decreasing abundance of DAT on the plasma membrane. Dopamine transporter and DRD2 
co-expressed in oocytes, treated with a DRD2 agonist, exhibited upregulated expression of 
DAT on the plasma membrane. Treatment with pertussis toxin blocked the effect, further 
implicating DRD2 (Mayfield and Zahniser, 2001), as the DRD2 receptor is coupled to G-
inhibitory proteins Gai and Gao (Ben-Jonathan and Hnasko, 2001). Interestingly, DAT is 
also able to directly bind to the third intracellular loop of DRD2 resulting in upregulation 
of DAT at the plasma membrane (lee et al., 2007). 
Dopamine transporter protein expression and availability are regulated by post-
translational modification. The DAT transporter plasma membrane expression has been 
observed to be PKC dependent (Grånäs et al., 2003). Truncation of the first 22 residues of 
the N-terminal results in a loss of phosphorylation, however, no changes in internalization 
(Grånäs et al., 2003). Internalization regulation seems to be mediated on the C-terminal, 
specifically residues 587-590 (Boudanova et al., 2008). The predicted mechanism for 
regulation of internalization of DAT includes an endocytic “brake.” The proposed brake 
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closely associates with DAT residues 587-590 to decrease binding to an adaptor protein 
necessary for internalization. Once PKC is activated the brake dissociates from DAT and 
the resulting residues are free to associate with the adaptor protein to facilitate endocytosis 
(Boudanova et al., 2008).  
Dopamine transporters can be recycled back to the plasma membrane or marked 
for lysosomal degradation by ubiquitination (Miranda et al., 2007). Experiments to induce 
mutations in ubiquitination proteins such as a protein ubiquitination E3 ligase protein 
(Parkin) have been observed to increase degradation of misfolded DAT (Jiang and Feng, 
2004). A mechanism for ubiquitination has been proposed with another implicated 
ubiquitin, neural precursor cell expressed developmentally down-regulated protein 4 
(NEDD4-2) or through PKC mediated phosphorylation (Miranda et al., 2007). After 
activation of NEDD4-2 or by phosphorylation, ubiquitinated DAT is transported to a 
clathrin-coated pit by binding to Eps15 subsequently could to AP-2 on the clathrin coated 
pit. The ubiquitinated DAT is endocytosed and degraded by lysosomes as endosomes 
mature. Non-ubiquitinated DAT is recycled back to the plasma membrane through 
extensions of multi-vesicular recycling endosomes (Miranda et al., 2007). Glycosylation 
of DAT transporters occurs within asparagine binding sites between transmembrane 
domains 3 and 4 (Nirenberg et al., 1996). Site directed mutation experiments revealed that 
mutation of all three N-linked glycosylation sites of DAT transporters strengthened the 
inhibitory action of cocaine on dopamine uptake (Li et al., 2004).  
Function in male reproduction 
 35 
Lack of or increased dopamine is associated with many mental health issues such 
as schizophrenia, Parkinson’s disease, and depression, all of which have been reviewed 
extensively (Meltzer and Stahl, 1976; Lotharius and Brundin, 2002; Dunlop and Nemeroff, 
2007). These conditions are treated with dopamine antagonistic and agonistic drugs that 
are known to cause a variety of side effects in male patients. Symptoms range in severity 
from sexual dysfunction (Segal et al., 1979) to infertility (Segal et al., 1976). These drugs 
are classified as neuroleptics and are known to cause hyper- or hypoprolactinemia 
depending on whether they are dopamine antagonistic or agonistic drugs, respectively 
(Dickson and Glazer, 1999). Specifically, hyperprolactinemia is associated with high 
instance of male infertility (Segal et al., 1976) and impotence (Segal et al., 1979). 
Hypoprolactinemia has been associated with reduced semen quality (Gonzales et al., 1989) 
and decreased libido (Svare et al., 1979).  
Cattle consuming a forage containing a dopaminergic agonist experience lowered 
serum PRL concentrations and exhibit similar repercussions on reproductive physiology 
including decreased cleavage rates of oocytes fertilized with semen from bulls grazing 
fescue infected with a dopamine agonist and decreased semen quality and freeze-thaw 
survivability (Schuenemann et al., 2005; Pratt et al., 2015). Others report no change in 
semen quality (Schuenemann et al., 2005; Stowe et al., 2013). Dopamine type-2 receptors 
are present in spermatozoa of cattle, rats, mice, humans (Otth et al., 2007) and boar 
(Ramírez et al., 2009). Receptors are also present in mouse Leydig cells (Gonzalez et al., 
2015). The presence of DRD2 receptors in Leydig cells and sperm cells suggests a direct 
role for dopamine signaling in steroidogenesis and spermatogenesis. Report of a role for 
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dopamine in capacitation in vitro in pig sperm confirms functionality of dopamine 
signaling in male germ cells (Ramírez et al., 2009). Indeed, lower cleavage rates were 
observed in oocytes fertilized with semen from bulls grazing fescue infected with a 
dopamine agonist (Schuenemann et al., 2005). However, the majority of the literature does 
not support a direct effect of dopamine to DRD2 receptors on sperm cells, and instead 
research has focused on an indirect mechanism, as most of the work performed has focused 
on dopaminergic agonist and antagonists and their effects on the PRL signaling pathway. 
Dopamine Receptors 
Structure 
Dopamine receptors are G-coupled, seven-transmembrane receptors (Missale et al., 
1998). The receptors are classified as either D1-like, including dopamine type-1 (DRD1) 
and dopamine type-5 (DRD5) receptors or D2-like, including dopamine type-2, 3, and 4 
receptors (DRD2, DRD3, DRD4; respectively). The DRD2 cDNA has been characterized 
and identified in human and cow pituitary (Senogles et al.,1988; Grandy et al.,1989), and 
in the rat brain (Bunzow et al., 1988). Human, rat, and cattle DRD2 cDNA share over 90% 
sequence identity among their amino acid sequence and ~85-90% shared identity in 
nucleotide sequence predicted through cDNA characterization (Grandy et al., 1989; Chio 
et al.,1990). The cattle DRD2 cDNA sequence is longer than the rat mRNA sequence and 
results in a protein product of 444 amino acids (Chio et al.,1990) compared to the rat 
sequence at 415 amino acids (Bunzow et al., 1988). Unlike the D1-like receptor genes that 
are intronless, the D2-like receptor gene contains 6 introns and 7 exons and encodes for a 
predicted protein of ~50 kDa in size (Civelli et al., 1993). Alternative splicing of an extra 
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exon encoding the additional 29 amino acids between introns 4 and 5 occurs in humans to 
produce different gene products, designated DRD2L and DRD2S for the long and short 
isoforms of the DRD2 receptor, respectively (Dal Toso et al., 1989). Isolation and 
characterization of DRD2 cDNA in cattle and rat brain encode for an extra 87 bp insert. 
The cDNA sequence was predicated to encode an extra 29 amino acids from this insert, 
located in the third intracytoplasmic loop (Chio et al., 1990).  The sequence was 
homologous to the earlier identified human sequence confirming cattle also undergo 
alternative splicing to produce DRD2S and DRD2L (Chio et al., 1990). 
The dopamine receptor type-3 cDNA was isolated and characterized in rat brain 
(Sokoloff et al., 1990). The DRD3 gene consists of five introns and six exons, 446 amino 
acids in length. The amino acid sequences of DRD2 and DRD3 share high identity 
among their transmembrane domains at ~75%; however, given the entire amino acid 
sequences, the two receptors only share ~50% sequence identity (Sokoloff et al., 1990).  
The DRD4 cDNA has been characterized in humans (Van Tol et al., 1991), rats (Sun et 
al., 1998), and the mouse (Suzuki et al., 1995). The gene contains five exons and encodes 
for a predicted protein of 387 amino acids in length (Van Tol et al., 1991). Like DRD3, 
the human DRD4 protein also shares high amino acid sequence identity to DRD2 when 
considering transmembrane domains alone; however, DRD4 shares the least homology to 
all D2-like receptors overall, when considering the entire amino acid sequence (Van Tol 
et al., 1991). Unique to the human DRD4 amino acid sequence are transposable element 
repeats that have been identified in the coding region (Lichter et al., 1993). Each variant 
is designated DRD4.3, DRD4.6, and DRD4.9 with the end digit corresponding to the 
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number of repeats. Repeats have been found in various locations throughout the DRD4 
gene, Specifically within the third cytoplasmic loop. Repeats within DRD4 have been 
hypothesized to effect RNA stability and expression (Schoots and Van Tol, 2003) but are 
likely not involved in G-protein interactions or enhancement of functional activity for 
binding of dopamine agonistic drugs (Asghari et al., 1995; Jovanovic et al., 1999). 
Dopamine type-1 receptor has been characterized and is present in human retina 
(Dearry et al.,1990), rat striatum (Monsma et al., 1990), and in cattle lung, kidney, and 
uterus (Haegeman et al., 1999). The cDNA encoded for a protein 446 amino acids in 
length with a molecular weight of 49 kDa. Similarly, DRD5 also has been characterized 
in cattle and is present in the lung and kidney, encoding for a protein 477 amino acids in 
length. Dopamine type-5 receptor shares 50% amino acid sequence identity with its 
counterpart, the DRD1 receptor (Sunahara et al.,1990). A conserved cysteine residue is 
located at the end of the D1-like receptor carboxyl terminal and at the beginning of D2-
like receptor carboxyl terminal (Missale et al., 1998). Two conserved cysteines are also 
located in the extracellular loops 2 and 3. The cysteine residues have been implicated in 
other G-coupled receptor types to form a disulfide bridge for facilitation of ligand 
binding (Dohlman et al., 1989). There are two N-glycosylation sites in D1-like receptors 
and up to 4 in D2-like receptors (Civelli et al., 1993). Mutation experiments reveal that 
receptor activation and signal transduction is dependent on a conserved aspartate residue 
80 (Neve et al., 1991). When asp80 was substituted for an adenine or guanine the DRD2 
receptor lost its ability to inhibit adenylyl cyclase, as is necessary for the negative 
feedback on PRL (Neve et al., 1991). 
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Signaling pathways 
Dopamine receptors have been categorized based on their ability to inhibit or 
stimulate adenylyl cyclase activity. In general, D1-like receptors stimulate adenylyl cyclase 
activity (Monsma et al., 1990). Experiments have demonstrated DRD1 receptor’s ability 
to stimulate cAMP production by transfection of COS-7 cell lines with the DRD1 transcript 
followed by treatment with DRD1 agonists (Monsma et al., 1990). Further, activation of 
adenylyl cyclase was measured by conversion of ATP to cAMP and was associated with 
expression of GTP-binding proteins, Golf rather than Gs detected by immunoblotting in the 
striatum of rats (Hervé et al., 1993). Dopamine type-1 receptor is bound by dopamine 
prompting a conformational change. The conformational change prompts dissociation of 
the alpha subunit of the GTP-binding proteins, Gs/olf. Once activated, adenylyl cyclase 
initiates the production of cAMP and subsequent activation of PKA. Activated PKA 
phosphorylates CREB that binds to CRE domains and subsequently binds cAMP binding 
proteins. Consequently, binding of cAMP binding protein facilitates activation of 
regulatory elements on the DNA (Nishi et al., 2011). 
  Dopamine type-2 like receptors work the opposite of D1-like receptors in that they 
inhibit adenylyl cyclase (De Camili et al., 1979). Primary examples of its inhibition are 
through the actions of dopamine binding DRD2 on lactotrophs for suppression of PRL 
synthesis and secretion (Ben-Jonathan and Hnasko, 2001). The inhibition of adenylyl 
cyclase is facilitated through coupling of the DRD2 receptor with adenylyl cyclase by GTP-
binding proteins Gai and Gao (Enjalbert et al., 1988). Binding of dopamine to DRD2 
induces a conformational change resulting in dissociation of the alpha subunit of the GTP-
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binding protein trimer. The alpha subunit couples to and inhibits adenylyl cyclase, 
preventing activation of PKA, phosphorylation of CREB, and further, downstream 
transcriptional activation (Figure 1.4) (Ben-Jonathan and Hnasko, 2001; Lledo et al., 
1992). 
D2-like receptors can also mediate inhibition of PRL signaling through inhibition 
of the Ras-Raf-MEK-ERK pathway. Dopamine binds to DRD2 and a conformational 
change takes place that prompts Gao GTP-binding protein subunit to dissociate from the 
G-protein trimer. Coupling of Gao  GTP-binding protein subunit inhibits the activation of 
ERK1 and ERK2 in GH4ZR7 cells (Liu et al., 2002). The mechanism of action is not 
known yet, although it is hypothesized that the mechanism may be through coupling to 
adenylyl cyclase or ion channels. Utilizing transgenic mice for either the DRD2 long or 
DRD2 short receptor types, induction of the Ras-Raf-MEK-ERK pathway has been 
measured in which overexpression of the short isoform resulted in increased 
phosphorylation of ERKs and pituitary hypoplasia and reduced serum PRL compared to 
the long isoform which decreased phosphorylation of ERKs when overexpressed in the 
pituitary and increased PRL (Laccarino et al., 2002). These results indicate that differential 
expression of particular DRD2 isoforms adds yet another layer of control over PRL protein 
expression and cell proliferation by induction of the Ras-Raf-MEK-ERK pathway (Figure 
1.4). 
Both D1- and D2-like receptors have the ability to regulate ion channels in order to 
elicit effects at the cellular level. Inositol phosphate accumulation has been observed in the 
rat striatum (Undie and Friedman, 1990). Slices of rat brain subjected to treatment with 2-
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[3H]inositol (for incorporation into inositol phosphates) and treatment with DRD1 agonists, 
indicated stimulation of inositol phosphates through DRD1 signaling (Undie and 
Friedman, 1990). A dose effect was observed with peak inositol phosphate accumulation 
at 100µM concentration of a dopamine agonist was required to elicit calcium mobilization 
through D1-like receptor signaling with the effect absent at lower doses in rats. Dopamine 
like-2 receptors function to inhibit calcium influx through interaction of GTP-binding 
proteins with ion gated channels (Lledo et al., 1992). Much of the research on 
hyperpolarization claims inhibition of PRL also occurs by coupling of DRD2 to activate 
potassium channels (Einhorn, Gregerson, and Oxford, 1991). Coupling is facilitated by the 
GTP-binding protein beta and gamma subunits interaction with gated inward-rectifying 
potassium channels, increasing potassium conductance and causing calcium channels to 
close resulting in decreased intracellular calcium (Pillai et al., 1998). Contrary to D2-like 
receptors, D1-like agonists were shown to inhibit activation of potassium channels 
(Surmeier and Kital, 1993). 
Synthesis and export trafficking 
Synthesis and folding of the G-coupled receptor occurs within the endoplasmic 
reticulum and the newly synthesized receptor must be transported to the plasma membrane 
(Rothman, 1994). The receptors are packaged into vesicles known as coat protein two 
(COPII) vesicles, or the coated protein vesicular transport system. The G-coupled receptor 
is taken up by the vesicles due to interactions between the receptor and COPII proteins 
(Kunduri et al., 2014). The receptors are not yet mature and must make their way from the 
endoplasmic reticulum, through the Golgi apparatus and the trans-Golgi network 
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(Rothman, 1994). As they make their way through the Golgi, receptor proteins undergo 
post translational modifications until they are sequestered to the plasma membrane. Aside 
from transport of the newly synthesized receptor, proteins meant to assist in folding and 
post-translational modification travel with the receptor to its destination. These chaperone 
proteins often act as quality control for the transported G-coupled receptor. This has been 
established between calnexin and a vasopressin receptor in a pulse chase experiment with 
mutated and wild type forms of the receptor (Morello et al., 2001). The vasopressin 
receptor with a nonsense mutation induced in the proximal portion of the carboxyl tail was 
maintained in the endoplasmic reticulum in association with calnexin longer than wild-type 
receptors, hypothesized to be unrecognizable by the chaperone proteins needed for 
transport to the plasma membrane (Morello et al., 2001). The dopamine receptor exits the 
endoplasmic reticulum by interaction of the COPII protein with chaperone protein motifs, 
or in the case of the DRD1 receptor, interaction with the DRiP78 protein (Bermak et al., 
2001). In particular, the interaction with DRiP78 protein occurs at the FxxxFxxxF motif 
which has been identified in the DRD1 receptor C-terminal (Bermak et al., 2001). 
Trafficking mechanisms of DRD2 are not yet fully understood; however, Leucine-rich 
repeat kinase 2 (LRRK2) has been associated with decreased trafficking to the membrane, 
as DRD2 was localized to the Golgi when LRRK2 was overexpressed in a neuroblastoma 
cell line (Rassu et al., 2017). 
Once the G-coupled protein receptor exits in the Golgi, export to the plasma 
membrane is facilitated by Rab 1 as shown in other G-coupled receptor types (Wu et al., 
2003). Although the mechanism is not fully understood, Rab1 mutation and distribution 
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studies with adrenergic and angiotensin receptors show that mutation of Rab1 results in 
much less cell surface receptors (Wu et al., 2003). Internalization of DRD2 receptors at the 
membrane is performed for recycling of receptors. In the case of D2 receptors, a GTPase 
(dynamin), a Ras related protein (Rab5a) and G-protein coupled receptor kinase 2 (GRK2) 
facilitate internalization. Specifically, GRK2 is co-expressed with DRD2 upon 
internalization. Dynamin has been hypothesized to phosphorylate DRD2 and close the 
vesicles for internalization whereas Rab5a facilitates binding to the clatharin coated pit 
where internalization occurs (Iwata et al., 1999). In some cases, degradation is triggered 
by lysosomal degradation facilitated by Rab7, as Rab7 was found localized to the cell 
membrane of late endosomes by immunofluorescence (Chavrier et al., 1990). 
Single Nucleotide Polymorphisms 
Single nucleotide polymorphisms within the DRD2 gene 
 Single nucleotide polymorphisms are defined as single base changes within the 
DNA across individuals in a given population. These substitutions must occur > 1 % in any 
given population to be considered a SNP and can occur within coding and non-coding 
regions of the DNA to alter gene expression as well as protein structure or function (Kwok 
and Gu, 1999). The PRL signaling pathway has been implicated in effects on reproductive 
efficiency of several species and may provide a route for indirect effects on mammalian 
reproduction (Gonzales at al., 1989; Schuenemann et al., 2005). Some of these indirect 
effects may be explained by the presence of SNPs reported to be present in the bovine 
DRD2 gene (Campbell et al., 2014). Evidence for impact on male physiology due to 
dopaminergic SNPs exist. 
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An insertion/deletion SNP occurring in the promoter region of the DRD2 gene at 
position 141 across two cytosines in tandem, was highly associated with sexual dysfunction 
in men treated with DRD2 antagonist drugs. The three resulting genotypes are 
insertion/insertion, insertion/deletion, and deletion/deletion. Men with the cytosine 
deletions, whether they are homozygous or heterozygous for cytosine deletion, had overall 
lower blood PRL levels (Zhang et al., 2011). The polymorphism is located in the SP1 
binding site of DRD2 (Arinami et al., 1997). The DRD2 lacks a TATA promoter sequence 
and relies on SP1 binding sites for promoter activity (Minowa et al., 1992; Yajima et al., 
1998). The deletion genotype has been associated with higher density of DRD2 in the 
striatum in humans (Jönsson et al., 1999) suggesting this polymorphism may alter promoter 
activity and therefore DRD2 gene expression. Subsequently, PRL protein expression may 
be altered in deletion genotype patients due to the increased repression of PRL secretion 
by elevated DRD2 availability and signaling. 
Another polymorphism resulting in a base change between cytosine and thymine in 
exon 7 at position 3420 of the human DRD2 gene (encoding the cytoplasmic portion of 
DRD2) has been reported to be associated with hyperprolactinemia (Hansen et al., 2005). 
The cytoplasmic portion of DRD2 functions in docking of inhibitory G-proteins (Missale 
et al., 1998) that facilitate inhibition of PRL (Ben-Jonathan and Hnasko, 2001). The 
polymorphism is silent and, therefore, does not change the amino acid sequence. Patients 
with the cytosine to thymine substitution resulting in a homozygous genotype were 
associated with increased occurrence of hyperprolactinemia (Hansen et al., 2005), 
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suggesting the base change may impact gene expression of the PRL pathway by altering 
G-coupled protein interactions. 
Recently, a SNP was reported in cattle indicating an association to serum PRL 
concentrations in steers grazing a forage containing a dopamine agonist (Campbell et al., 
2014). The DRD2 SNP is located within the third intron at position 404365, on 
Chromosome 15, inferring a base substitution between adenine and guanine (Campbell et 
al., 2014). Steers grazing the dopaminergic agonist in April and May, but not in June 
months, that possessed a genotype homozygous for an ‘A’ allele, were associated with 
higher serum PRL concentrations compared to those homozygous for a ‘G’ allele. 
Association of decreased PRL in GG steers was also observed to have increased hair coat 
scores. Homozygous ‘A’ heifers were also observed to have fewer days to first calf 
(Campbell et al., 2014). The same base substitution between adenosine and guanine on the 
DRD2 gene tended to be associated with hair coat score but had no effect on calving rates 
in Angus crossbred cows (Meyer et al., 2016). Elevated circulating PRL concentrations 
have been observed to cause reduced hair coat shedding in the summer months (Porter and 
Thompson, 1992); however, serum PRL concentrations were not measured, therefore 
associations of genotype to serum PRL concentrations were not explored. 
Contrary to DRD2 SNPs in humans, the bovine DRD2 SNP is located within a non-
coding region, and therefore would not affect protein structure/function however, its effects 
on PRL release and synthesis could be due to effects on gene expression within the PRL 
signaling pathway. An example could be the SNP alters mRNA transcript stability. Other 
DRD2 intronic SNPs have been reported to affect transcript abundance, and have also been 
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associated with increased binding of transcriptional repressors that decrease DRD2 mRNA 
expression in human striatum (Rogaeva et al., 2007). Conflicting research on male 
reproductive function due to exposure to a dopamine agonist warrants further investigation. 
Single nucleotide polymorphisms in the DRD2 gene have been associated to serum PRL 
concentrations (Campbell et al., 2014) which would provide an indirect mechanism in 
which binding of these agonists to DRD2 affect PRL, and therefore male reproductive 
function. Contrary to the prior findings, preliminary data from our lab indicate that DRD2 
genotype (Campbell et al., 2014) does not impact male physiology, having little or no effect 
on semen quality parameters or prolactin serum concentrations in bulls grazing a dopamine 
agonist. Investigation of DRD2 genotype association with PRL protein and mRNA 
expression would be beneficial to perform directly at the source of PRL production, in the 
bovine pituitary to clarify the intronic SNP’s association with decreased serum PRL 
concentrations in cattle.  
Single nucleotide polymorphisms in genes within the PRL signaling pathway 
 Aside from SNPs in the DRD2 gene, other variants located within the PRL (Brym 
et al., 2005a; Looper et al., 2010), PRLR (Brym et al., 2005b), and STAT5 (Brym et al., 
2004) genes have been reported. These SNPs have been implicated in association to 
productivity traits in cattle and may also provide more routes in which PRL synthesis and 
release may be affected that may subsequently impact bull reproduction. 
 A cytosine to thymine substitution at position 1286 of the PRL gene, within the 
promoter region was identified in cattle (Looper et al., 2010). Cattle grazing a forage 
containing a dopamine agonist possessing a homozygous thymine genotype had reduced 
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calving rates than those heterozygous or homozygous cytosine cows (Looper et al., 2010). 
Further, a second SNP was identified in the promoter region, an adenine to guanine 
substitution at position 1167. Cow possessing a lower BCS containing a ‘G’ allele had 
longer time to calving (Looper et al., 2010). An adenine to guanine substitution in position 
8398, in exon 4 of the PRL gene, was associated with milk yield in cows (Brym et al., 
2005a). Dairy cows with a heterozygous genotype had higher milk yields than homozygous 
individuals of either ‘A’ or ‘G’ alleles and homozygous ‘G’ cows yielded milk higher in 
fat (Brym et al., 2005a). Being located in the promoter region suggests that the SNPs could 
impact initiation of transcription directly. 
 Similar to the intronic DRD2 SNP reported in cattle (Campbell et al., 2014), 
intronic SNPs have been reported in the bovine STAT5 gene in intron 9, position 9501, 
including an adenine to guanine substitution (Brym et al., 2004). Jersey cows, but now 
black and white dairy cows possessing a genotype with an ‘A’ allele, either heterozygous 
or homozygous, were associated with higher protein content in milk while cows 
homozygous for a ‘G’ allele had overall higher milk yield (Brym et al., 2004). An intronic 
SNP has also been reported within the PRLR gene within intron 9 at position 205 (Brym 
et al., 2005b). The intronic SNP includes a substitution for adenine to cytosine. Jersey cows 
homozygous for a ‘C’ were associated with milk yielding higher protein content (Brym et 
al., 2005b). The SNPs located in a non-coding region are not likely to effect protein 
structure but could affect gene expression of STAT5. The possibility exists that 
downstream effects for activation of transcription by binding of STAT5 dimers to GAS 
sequences necessary for the activation of transcription of casein genes may also be effected. 
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 The presence of SNPs in genes involved in the PRL signaling pathway, already 
associated with productivity traits in cattle, could serve as potential targets of future studies 
on associations of these SNPs to PRL gene expression and further, reproductive and growth 
traits in bulls. To the best of our knowledge, SNPs within the Ras Raf MEK ERK pathway 
have not been reported in association with reproduction traits or PRL serum concentrations 
in cattle and could also be investigated. 
Conclusions 
 Prolactin (PRL) is a ~22 kDa peptide involved in over 300 diverse biological 
functions (Freeman et al., 2000). This peptide is produced by lactotrophs in the anterior 
pituitary, and it’s release and synthesis is negatively regulated via tonic inhibition by 
dopamine through the dopamine type-2 receptor (DRD2) (Ben-Jonathan and Hnasko, 
2001). Once released, PRL in circulation binds to its ubiquitously expressed receptor, 
activating the JAK-STAT pathway (Campbell et al., 1994). Janus 2 kinases bind to the SH2 
domain on the cytoplasmic portion of the receptor and are phosphorylated upon PRL 
binding. This phosphorylation of JAK triggers the association and phosphorylation of 
STAT5 (Ihle, 1996). STATs dimerize and translocate to the nucleus to stimulate gene 
transcription by binding to defined nucleic acid sequences within promoter regions of 
genes (Ihle, 1996). Dopamine receptors are G-coupled protein receptors. Coupling of 
DRD2 to G-inhibitory proteins functions to inhibit PRL gene expression by suppression of 
adenylyl cyclase and therefore cAMP production (Ben-Jonathan and Hnasko, 2001). More 
immediately, upon binding of dopamine to DRD2 on lactotrophs, a rapid decrease in 
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intracellular calcium occurs suppressing the release of PRL from secretory granules (Ben-
Jonathan and Hnasko, 2001).   
 Cattle consuming forage containing a naturally occurring dopamine agonist, exhibit 
reduced circulating serum concentrations of PRL (Schillo et al., 1987; Strickland et al., 
2011; Pratt et al., 2014). Consumption of dopamine agonists have been reported to decrease 
sperm motility and morphology in bulls (Looper et al., 2009; Pratt et al., 2015). Receptors 
for dopamine and PRL have been reported to be present in male reproductive tissues (Hair 
et al., 2002; Otth et al., 2007; Pratt et al., 2014), therefore, either hormone may have an 
effect on male reproduction. Antipsychotic drugs used in human medicine also 
antagonistically bind dopamine receptors (Seeman et al., 1975) and patients taking these 
dopamine antagonists experience erectile dysfunction as well as increased latency in time 
to ejaculate (Segraves, 1989). In humans, hyperprolactinemia is associated with infertility 
(Segal et al., 1979) and impotence (Segal et al., 1976) while hypoprolactinemia is 
associated with reduced semen motility in male patients (Gonzales et al., 1989). Moreover, 
early PRL and PRL receptor ablation experiments in mice resulted in infertile males 
(Ormandy et al., 1997). The mechanism in which male reproductive physiology is impacted 
could be due to either dopamine through binding of the DRD2 receptor at the level of the 
testis and accessory glands or due to lowered serum PRL concentrations.  
 The PRL signaling pathway has been implicated in effects on reproductive 
efficiency of several species and may provide a route for indirect effects on mammalian 
reproduction (Flisikowski et al., 2003; Hermanns and Hafez, 1981; Ormandy et al., 1997; 
Segal et al., 1976). Some of these effects may be explained by the presence of single 
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nucleotide polymorphisms. The SNPs could impact signaling through DRD2 or PRL 
signaling and therefore could affect mammalian reproductive physiology. Evidence for 
impact on male physiology due to dopaminergic SNPs exist. A polymorphism in DRD2 
exon 7 in which homozygosity is prevalent results in a high association with male infertility 
and impotence (Hansen et al., 2005). Further, a cytosine insertion in the DRD2 gene has 
been shown to impact PRL secretion as measured by increasing blood serum 
concentrations leading to erectile dysfunction (Zhang et al., 2011). A SNP has been 
identified that exists within the bovine DRD2 gene, within an intron, consisting of a base 
substitution between adenine and guanine (Campbell et al., 2014). Similarly, to humans, 
this SNP is associated with decreased serum PRL concentrations in cattle consuming 
dopamine agonists (Campbell et al., 2014). Other SNPs within genes involving the PRL 
signaling pathway have been reported within PRL (Looper et al., 2010), PRLR (Ormandy 
et al., 1997), and STAT5 (Brym et al., 2004) genes. These SNPs have also been implicated 
in association to productivity traits in cattle and may also alter PRL synthesis and release 
to subsequently impact bull reproductive physiology. 
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Figure 1.1 Dopamine type-2 receptor mediated inhibition of PRL synthesis and 
release by Gi/o inhibition of adenylyl cyclase.  
 Dopamine binds to DRD2 coupled with G-inhibitory proteins alpha (µ), Beta (b), 
and Gamma (g). Ligand binding initiates a conformational change of the receptor. An 
exchange of GDP for GTP on the alpha subunit of the coupled G-inhibitory protein results 
in activation and dissociation of the alpha subunit from the beta and gamma subunits. (1) 
GTP-binding protein b and g subunits interact with gated inward-rectifying potassium 
channels that stimulate potassium conductance. As a result, calcium channels close 
resulting in decreased intracellular calcium and hyperpolarization of the cellular 
membrane, decreasing secretion of PRL. (2) Interaction of alpha subunit Gi/o with adenylyl 
cyclase suppresses production of cAMP, activation of protein kinase A (PKA), and 
therefore, downstream PRL gene expression. Interactions of the alpha subunit are marked 
by double-pointed black arrows.  Inhibition is marked by red decreasing arrows and 
increases in expression or abundance are marked by upward facing green arrows. 
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Figure 1.2 Dopamine type-2 receptor mediated inhibition of PRL synthesis and 
release by Gi/o inhibition of phospholipase C (PLC) and protein kinase C (PKC). 
 Dopamine binds G-coupled DRD2. A conformational change occurs due to ligand 
binding and GDP is exchanged for GTP. The alpha (a) subunit disassociates from the beta 
(b) and gamma (g) subunits and is able to associate with other proteins to facilitate 
inhibition. Inhibition of phospholipase C (PLC) prevents subsequent hydrolysis of 
phosphatidylinositol 4,5-bisphosphate (PIP2) and production of intermediates Inositol 
triphosphate (IP3) and Diacyl glycerol (DAG). Normally inositol triphosphate functions to 
bind to IP3 receptors for activation of voltage gated channels in the endoplasmic reticulum 
to allow for calcium influx needed for secretion of prolactin while DAG and calcium 
activate PKC. Inhibition of PLC prevents intermediate formation and activation of PKC 
needed for phosphorylation of transcription factors necessary for transcriptional activation 
of the PRL gene. Inhibition is marked by red decreasing arrows. 
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Figure 1.3 Prolactin stimulation of Janus kinase 2 (JAK2) and signal transducers and 
activators of transcription 5 (STAT5).  
 Ligand binding induces dimerization and a conformational change occurs in the 
cytoplasmic region of the  PRLR. The constituativley active JAK2 is activated following 
auto phosphorylation of tyrosine residues on the receptor providing docking sites for 
STAT5 molecule. STAT5, in close proximity to JAK2 is also phosphorylated. The STAT5 
molecules then disassociate from the receptor, dimerize, translocate to the nucleus to bind 
to CIS elements on the DNA. Activation of a MAPK pathway, the Ras/Raf/MEK/ERK 
cascade is also possible through bridging of the two signaling pathways by adaptor proteins 
SHC, GrB2, and SOS. Phosphorylated tyrosine residues on the PRLR serve as docking 
sites for the adapter proteins to bind. Activation of Ras, Raf, and MEK1/2 permit the 
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activation of ERK1/2 that translocate to the nucleus to modulate transcription factors such 
as ETS factors. 
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Figure 1.4 Antagonistic effects of dopamine receptor type-1 (DRD1) and dopamine 
receptor type-2 (DRD2).  
 Dopamine type-1 (D1) receptor is associated with GTP-binding proteins, Gs/olf and 
Dopamine type-2 receptors (D2) are associated with signaling by GTP-binding proteins, 
Gi/o. Once bound by ligand, a conformational change of the receptors occurs prompting the 
dissociation of GTP-binding protein a subunits. GTP-binding proteins, Gs/olf associates 
with and prompts stimulation of adenylyl cyclase activity followed by production of cAMP 
and subsequent activation of PKA. Activated PKA phosphorylates CREB that binds to 
CRE domains and subsequently binds cAMP binding proteins for stimulation of 
transcription. Dopamine type-2 receptor GTP-binding proteins Gi/o bind to and inhibit 
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adenylyl cyclase therefore preventing the signaling cascade for activation of PKA, 
phosphorylation of CREB, and further, downstream transcriptional activation. 
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CHAPTER TWO 
BOVINE DOPAMINE TYPE-2 RECEPTOR SNP HAS NO EFFECT ON 
GROWTH, SEMEN CHARACTERISTICS AND PROLACTIN 
CONCENTRATIONS IN BEEF BULLS EXPOSED TO A DOPAMINE AGONIST 
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Abstract 
 A dopamine type-2 receptor (DRD2) SNP, previously found to be correlated with 
serum prolactin (PRL) concentrations in cattle, was evaluated for impact on growth traits, 
serum prolactin concentration, and semen quality. Over a four-year period, yearling beef 
bulls were allowed diets containing or lacking ergot alkaloids (EA). Every 21 or 28 d semen 
was collected for semen motility and morphology assessment and blood samples were 
collected to measure serum PRL concentrations. In addition, body condition score and 
scrotal circumference were evaluated. Serum PRL concentrations were assessed using a 
radioimmunoassay. In the first year, all bulls were sacrificed at the end of a 126-day study. 
Testicles and epididymis were collected at the end of the study or 60 days after removal 
from treatment. Immunohistochemistry was performed on testis, epididymis, and sperm 
cells, incubated with or without a primary antibody for DRD2 and counterstained with 
DAPI. Isolation of DNA was performed on sperm pellets using DNAzol (Thermo Fisher 
Scientific, Waltham, MA, USA) methods. Polymerase chain reaction was performed to 
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amplify the region of the DRD2 gene containing the SNP of interest. The products were 
subjected to restriction fragment length polymorphism analysis. Further, all samples were 
subjected to genotyping using a custom Taqman genotyping assay (Applied Biosystems, 
Foster city, CA, USA). The presence of DRD2 was detected in the testis, epididymis, and 
sperm cells. The DRD2 genotype was not associated with semen quality, serum PRL, or 
growth traits. Consumption of EA resulted in lesser PRL serum concentrations but had no 
effect on values for other variable examined. 
Introduction 
Prolactin (PRL) is an ~ 22 kDa peptide produced primarily by pituitary lactotrophs 
and is regulated by dopamine through tonic inhibition (Ben-Jonathan et al., 2001). Prolactin 
is involved in over 300 biological functions across species (Bole-Feysot et al., 1998; 
Freeman et al., 2000). Hyperprolactinemia promotes erectile dysfunction as well as 
infertility in men which improves through treatment with a dopamine agonist (Segal et al., 
1979). Dopamine is the main regulator of PRL via tonic inhibition (Ben-Jonathan et al., 
2001) and the bovine dopamine type-2 receptor (DRD2) gene possesses several single 
nucleotide polymorphisms (SNP), with one SNP reported to be correlated with serum PRL 
concentrations (Campbell et al., 2014). This SNP is located within intron 3 and therefore 
does not likely affect protein structure or function and currently there is little information 
available on the mechanism in which this SNP located in a non-coding portion of the gene 
(Campbell et al., 2014) acts. Currently all information is associative and little direct 
evaluation of the DRD2 SNP on PRL expression is available as well as little to no 
evaluation has been reported on this SNP’s impact on bull growth and reproduction.  
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Dopamine type-2 receptor genotype impact on PRL serum concentrations and hair 
coat scores was evaluated in steers consuming or not consuming forage containing ergot 
alkaloids (EA) (Campbell et al., 2014). The DRD2 SNP located within intron 3 at position 
nt 404365 on Chromosome 15, includes a base substitution between adenine and guanine 
at position 534 (Campbell et al., 2014). Dopamine type-2 receptor genotype was shown to 
be correlated with serum PRL concentrations, in which homozygous AA steers were 
associated with higher serum PRL concentrations compared to GG steers in April and May 
but not June months. While the DRD2 SNP (Campbell et al., 2014) is located within a non-
coding region and is not likely involved in protein folding or structure, the SNP may be 
involved in altering gene expression within the PRL pathway. Interestingly, the SNP does 
not appear to represent an alternate acceptor site to generate alternative splice variants of 
the DRD2 mRNA, nor has splice variants been reported for the bovine DRD2. Alternate 
splicing of DRD2 does occur to form long and short forms of the receptor to facilitate 
coupling of G-proteins and has been reported in the rat and human pituitary and brain (Dal 
Toso et al., 1989). Both, long and short forms of DRD2 are able to suppress PRL 
transcription (McChesney et al., 1991). However, this alternative splicing of DRD2 has not 
yet been reported in cattle. Evidence for effects on the PRL pathway due to dopaminergic 
SNPs exists with some continued differences in severity of effects in male physiology. 
Homozygosity of the polymorphism located on exon 7 of DRD2, was found to be 
associated with hyperprolactinemia in humans (Hansen et al., 2005). Moreover, an 
insertion-deletion located within the DRD2 promoter region was associated with sexual 
dysfunction and lower serum prolactin concentrations in human male patients (Zhang et 
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al., 2011). However, the aforementioned polymorphisms were not located within a non-
coding region such as the SNP of interest in this study. 
Cattle grazing forage producing EA, a naturally occurring dopamine agonist, 
possess decreased serum PRL concentrations (Schillo et al., 1988; Strickland et al., 2011). 
Ergot alkaloids can bind many neurotransmitter receptors (Larson et al., 1995; Mizinga et 
al., 1993; Schoning et al., 2001; Wang et al., 2009) to elicit physiological responses in 
cattle that consume them. Ergot alkaloids have been shown to act agonistically with DRD2, 
inhibiting the synthesis and secretion of prolactin (Caron et al., 1978; Paterson et al., 1995; 
Sibley et al., 1983; Thompson et al., 1993). Ergot alkaloid consumption may negatively 
affect semen motility and morphology (Looper et al., 2009; Pratt et al., 2015), as well as 
impact bull fertility (Schuenemann et al., 2005). However, there are contradictions between 
and within laboratories. Some report no change in semen quality (Schuenemann et al., 
2005; Stowe et al., 2013) or in vivo fertility in PRL knockout mice (Horseman et al., 1997). 
It is possible that EA may have an impact on male physiology by binding to DRD2 
receptors located in male reproductive tissues. Moreover, DRD2 is localized in the 
acrosome and tail regions of spermatazoa in bovine, rats, and mice, and is also present in 
spermatocytes and spermtids within the testes of rats. Further, dopamine type-2 receptors 
are also present in human spermatazoa, with the exception of the acrosome (Otth et al., 
2007). This is consistent across species with DRD2 receptors present in male reproductive 
tissues (Otth et al., 2007; Ramírez et al., 2009; Gonzalez et al., 2015). 
Results to date have demonstrated negative effects on growth traits in cattle 
exposed to a dopamine agonist. Earlier studies report a clear decrease in average daily gain 
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(ADG) in cattle grazing EA (Hoveland et al., 1984; Crawford et al., 1989) while other 
studies report no difference in BW or BCS between treatments of bulls with and without a 
dopamine agonist (Stowe et al., 2013). The decreased growth in animals grazing EA may 
be attributed to lower concentrations of growth hormone (GH). However, GH levels have 
been reported to increase across treatment of EA (Thompson et al., 1987) or remain 
unchanged (Paterson et al., 1995).  
With much variation in reports on growth and semen characteristics in cattle, 
clarification of the role of DRD2 genotypic effects is warranted. The objective of this study 
is to assess the presence of DRD2 in bovine testis, epididymis, and sperm and to assess if 
the DRD2 SNP (Campbell et al., 2014) has any impact on growth, semen quality, or serum 
PRL concentrations in bulls exposed to a naturally occurring dopaminergic agonist, EA. 
Materials and Methods 
Animals 
All animal research was approved by the Clemson University Institutional Animal 
Care and Use Committee (AUP #2010-068 and AUP # 2014-60).  
Experimental Design and Treatments 
Over four years, 2011 (n = 14), 2012 (n = 21), 2014 (n = 25) and 2015 (n = 29), 
yearling beef bulls were fed a ration that included or excluded ergot alkaloids. In 2011, 
bulls were fed a concentrate ration which contained or lacked tall fescue seeds containing 
or lacking EA at 0.8 µg/g dry matter (DM) (Stowe et al., 2013).  In all other years bulls 
were subjected to grazing forage that produced or lacked EA. Grazing treatments were 
performed according to Burnett et al. (2017). Bulls were subjected to electroejaculation 
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every 21 d for all animals in year 2011 with a total grazing period of 126 d. For all other 
years, electroejaculation was performed every 28 d with a total of 155 d for 2012 and 168 
d for years 2014 and 2015. Breeding soundness exams (BSE) were performed on all bulls 
to assess semen motility and semen morphology, scrotal circumference (SC), body 
condition (BCS) and structural soundness. Bulls passing the BSE were allotted to treatment 
and blocked according to body weight (BW) and BCS. Semen samples collected were 
centrifuged, separated into cell and fluid portions, and each individually stored at - 80° C 
until used for DNA isolation. Caudal venipuncture was performed to collect blood which 
was processed into serum. Blood was allowed to clot overnight at 4° C and serum was 
collected by whole blood centrifugation at 2000 x g for 15 min at 4° C and serum was 
stored at - 20° C. All bulls were sacrificed at the end of a 126-day study and testicles and 
epididymis collected either immediately at the end of the study (group A with 5 and 3 bulls 
on E- and E+ diet, respectively) or 60 days after removal from treatment (group B with 3 
bulls from each treatment) for year 2011 only. Data for growth, SC and semen quality from 
all animals in all years were assessed across periods 2 (0 d) through 5 (84 d). 
Radioimmunoassay 
Serum PRL concentrations were determined through a previously validated 
radioimmunoassay (RIA) performed by the F. Neal Schrick laboratory (Bernard et al., 
1993). The intra-assay coefficient of variation was 9.7 % and the inter-assay coefficient of 
variation was 6.0 % (Burnett et al., 2017).  
Immunohistochemistry and western Blotting 
 Formalin-fixed samples were processed and IHC performed as described by 
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Calcatera et al. (2011). Slides were washed in phosphate buffered saline (PBS) 3X, and 
incubated in blocking solution of 10 % goat serum/PBS for 15 min. Blocking serum was 
removed and sections were incubated with primary antibody for 1 hr at RT. A primary 
mouse monoclonal Ab for DRD2 (Sc-5303; Santa Cruz Biotechnology Inc., Dallas, Texas, 
USA) was diluted in blocking solution to a concentration of 4 µg/mL. Negative controls 
were treated with blocking solution in place of primary antibody. Following incubation in 
primary Ab, slides were washed in blocking solution followed by a final 1-hr incubation 
using secondary antibody, Alexafluor 594-conjugated goat anti-mouse IgG (A11032; 
Invitrogen, Carlsbad, CA, USA), diluted in blocking solution (10 µg/mL). After 
incubation, secondary antibody was removed and slides were washed in PBS. Nuclei 
staining was done by DAPI (0.33 µg/mL; Sigma, St Louis, MO, USA) and was followed 
by PBS wash as above. Slides were mounted with PBS, coverslipped, and immediately 
examined.  
Protein extracts were produced from cattle testis, epididymis and pituitary tissues 
by homogenization in a 1X RIPA buffer (Alfa Aesar, Ward Hill, MA) with addition of 
proteinase and phosphatase inhibitors at 10µl/mL (HALT; Thermo Scientific, Waltham, 
MA, USA). Concentrations of extracts were obtained using the DC microplate assay (Bio-
Rad; Hercules, CA, USA). Samples were processed by boiling 5 min in a 2X laemeli buffer 
with 1/8th volume beta mercaptoethanol. Denatured samples were centrifuged briefly and 
then loaded at 45µg total mass per well on a 12 % mini protean TGX precast gel (Bio-Rad; 
Hercules, CA, USA). Proteins were blotted onto a 0.2 µm nitrocellulose membrane (Bio-
Rad; Hercules, CA, USA). The membrane was blocked in 2.5 % non-fat dry milk Tris 
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buffered saline with added 0.1 % Tween 20 solution (TBST). Immunodetection was carried 
out using primary antibody against DRD2 (B-10) at 1:20 dilution (5303; Santa cruz 
biotechnology, Dallas, TX, USA) overnight at 4° C followed by three washes in TBST and 
an incubation with a goat anti-mouse IgG HRP conjugated secondary antibody (Sc-2031; 
Santa cruz biotechnology, Dallas, TX, USA) for 1 hr at RT. The membrane was washed 
again 3X in TBST followed by incubation with a clarity ECL western substrate (Bio-Rad; 
Hercules, CA, USA) for 5 min at RT. Chemiluminescent detection was performed in a 
Fluor Chem FC2 imager (Alpha Innotech; San Leandro, CA, USA) for 10 min. 
RNA isolation and RT-PCR 
Total RNA was isolated from testis and epididymis using the mirVana mRNA 
isolation kit (Ambion, Austin, Texas, USA). Purity of RNA was assessed by the nanodrop 
1000 spectrophotometer (Thermo Fisher Scientific, Wilmington, DE, USA) to obtain 
A260:A280 ratio. Quality was assessed using the Agilent 2100 bioanlayzer (Agilent 
Technologies Inc, Santa Clara, California, USA) ribonucleic acid integrity number (RIN), 
utilizing samples with an 8.0 or greater for analysis. Complimentary DNA was generated 
by reverse transcription reaction using Superscript II Frist-Strand kit (Invitrogen, Carlsbad, 
Ca, USA). Primers for DRD2 were generated through IDT PrimerQuest Tool (San Jose, 
CA, USA) for use in polymerase chain reaction (PCR), specific for bovine DRD2 
(NM_174043.2). corresponding to nucleotide positions 510-531 forward primer and 576-
597 reverse primer of the mRNA DRD2 sequence. End-point PCR was performed using 
GoTaq green (Promega Madison, WI, USA) and the resulting amplified cDNA was 
subjected to slab gel electrophoresis on 1.5 % agarose gels. In addition to size analysis PCR 
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products were ligated into pDrive cloning vectors and used to transform competent E. coli 
(Qiagen, Valencia, CA). Transformations were plated and subsequent colonies selected, 
propagated, and plasmid DNA isolated and subjected to dideoxysequencing. 
DNA isolation 
Sperm pellets were suspended in PBS to approximately 1X106 cells, as assessed by 
sperm quality analyzer (SQA) (Advanced Agricultural Technologies) or semen samples 
were aliquoted to 100µl for use in DNA isolation. Samples were centrifuged at 10,000 x g 
for 1 min, supernatant removed, and the sperm pellet washed in 100 µl of 1X PBS. For cell 
lysis, 1mL DNAzol (Thermo Fisher Scientific, Waltham, MA, USA) was added to each 
100µl semen sample with 1/8th volume of beta mercaptoethanol (BME). Cells were lysed 
by gentle pipetting. DNA was precipitated by addition of 500 µl of 100 % ethanol to each 
lysed sample. Samples were inverted until spooling of DNA was visible with a white 
precipitate. DNA was sedimented by centrifugation at 4,000 x g for 1 min. The supernatant 
was discarded and the pellet washed in 80 % ethanol (500 µl), centrifuged at 4,000 x g for 
1 min for a total of two washes. After the last wash, the DNA pellet was allowed to dry on 
the benchtop for 1 min, then resusupended in 100 µl 8mM NaOH. Samples were stored up 
to 1 week at 4° C until complete solubilization of the DNA was achieved. Samples were 
subjected to Nanodrop 1000 spectrophotometer (Thermo Fisher Scientific, Waltham, MA, 
USA) to determine A260:A280 ratio to assess purity.  
Genotyping 
Genotypes for each bull were obtained through restriction fragment length 
polymorphism (RFLP) analysis (Campbell et al., 2014) and Taqman SNP genotyping 
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assay. In brief, polymerase chain reactions were generated for a previously identified 
dopamine SNP region (Campbell et al., 2014). The subsequent products were purified 
using the wizard SV gel and PCR clean-up system (PROMEGA, Durham, NC, USA) and 
were subjected to slab gel electrophoresis for amplification of the dopamine SNP region 
(Campbell et al., 2014) to ensure amplification was successful. Purified products (200 ng) 
were digested using a Pfel (Tfil) restriction enzyme (New England Biolabs, Ipswich, MA, 
USA), allowed to digest at 37° C for 30 min. Slab gel electrophoresis was performed with 
each sample, digested and undigested. Digested samples yielded three genotypes with 
different size products; AA (532 and 261bp), AG (793, 532 and 261bp), and GG (793bp). 
A custom Taqman SNP genotyping assay (Applied Biosystems, Foster city, CA, USA) 
specific to the DRD2 SNP region (Campbell et al., 2014) was performed using 10 ng of 
the purified PCR products. Samples were run in 96-well format and run on the CFX Real-
Time System (BIO-RAD Hercules, CA, USA) for a single step at 95° C for 10 min 
followed by 40 cycles of denaturation at 92° C for 15 sec and annealing and extension at 
60° C for 1 min. Allelic discrimination analysis was performed using CFX Maestro 
software (BIO-RAD Hercules, CA, USA) to determine genotype. Sample of known 
genotype for each of the three genotypes were run on each plate as positive controls as well 
as a no template control (NTC). These results were compared to the RFLP analysis to 
ensure efficiency in genotype determination. 
Statistical analysis 
For serum PRL concentration, BW, BCS and semen characteristics, Analysis of 
Variance, followed by pairwise student’s t-tests among LSMeans was used to assess the 
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impact of genotype and EA treatment on semen quality and growth traits. The model for 
the Analysis of Variance included fixed effects for treatment, genotype, time on treatment 
and their interactions; and year as a random effect. The time on treatment effect was 
included in the model since animals in each year were assessed across periods 2 (0 d) 
through 5 (84 d). Equality of variances were examined by Levene’s test (P << 0.05). JMP 
software (SAS Institute Inc.) was used for all statistical calculations. 
Results 
DRD2 Expression in bull reproductive tissues 
The DRD2 receptor was identified to be present in the bovine testis, epididymis, 
and sperm using IHC (Figure 2.1); however, attempts using the same antibody in western 
blotting did not yield definitive results (data not shown).  To further confirm the presences 
of DRD2 gene products, end point (RT-PCR) and dideoxysequencing of the amplified 
product (Figure 2.1) were conducted and the expected product size and sequence were 
produced. The receptor was present in all samples examined regardless of treatment or bull 
genotype.   
Genotype frequencies 
Genotypic frequency was determined to be 18 % AA, 61 % AG, and 21 % GG 
using RFLP and 21 % AA, 59 % AG, 20 % GG by the custom Taqman genotyping methods 
across all years. Comparison of RFLP and Taqman DRD2 genotyping methods are shown 
(Figure 2.3). Genotypes were identical for all bulls with the exception of 3 animals across 
all years in the study. A representative sample is shown for each method RFLP and Taqman 
(Figure 2.4). 
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Growth, semen characteristics, and PRL serum concentrations 
Prolactin concentrations were not significantly changed across DRD2 genotype but 
showed a treatment effect, with higher concentrations of serum prolactin in bulls not 
consuming EA compared to bulls consuming EA (144.02 ng/mL ± 49.3; 53.10 ng/mL ± 
49.3, respectively (P < 0.05) (Figure 2.2). A year by treatment by genotype random effect 
was observed for PRL concentrations at a 37.6 % of total variance (P = 0.02).  As expected, 
period had a significant effect (P < 0.05) on BCS and BW with animals exhibiting a higher 
BCS and BW earlier in treatment. Period also effected scrotal circumference, with bulls at 
a lower scrotal circumference (35.4 ± 0.41; P < 0.05) at the start of the study, increasing 
up to 84 d (36.3 ± 0.44; P < 0.05) (Table 2.1). A random interaction including year, 
treatment, genotype, and period accounted for 9.7 % of the total variance for BCS (P = 
0.03) and 0 % for BW and SC (P < 0.0001). There were no significant differences in semen 
concentration due to treatment, period, genotype or their interactions. There were no 
differences in motility, progressive motility, number of motile sperm cells or number of 
progressively motile sperm cells due to treatment, period, genotype or their interactions. 
However, period effected velocity with bulls longer on study presenting elevated semen 
velocity (P < 0.05). Sperm cell morphology as well as the total number of sperm cells per 
ejaculate showed no significant differences. A random effect for cell morphology including 
treatment, year, genotype, and period accounted for none of the percent total variance (P = 
0.009). Further, no significance was seen for total motile sperm or total progressive motile 
sperm cells per ejaculate in relation to genotype, treatment, period or their interactions 
(Table 2.2). 
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Discussion 
There is contradiction between observations in the body of literature surrounding 
the topic of dopamine agonist effects on male reproduction and physiology. The reason for 
the variability may be attributed to genetic makeup of animals utilized in the studies.  This 
study evaluated the presence of DRD2 expression in bovine male reproductive tissues and 
assessed genotypic differences in animals for the DRD2 gene in an attempt to determine 
any possible differences in bovine male physiology due to a particular DRD2 SNP 
(Campbell et al., 2014) on bull serum PRL concentration, growth traits, and semen quality 
in bulls grazing a dopamine agonist. Using IHC techniques, the DRD2 receptor was found 
to be present in bull testis, epididymis and sperm.  This is similar to observations in other 
species showing the presence of DRD2 receptor throughout the male reproductive system, 
including sperm cells (Gonzalez et al., 2015; Otth et al., 2007; Ramírez et al., 2009).  To 
further verify the expression of DRD2 receptor in male reproductive tissues, end-point RT-
PCR identified products of the correct size and sequence. The primers utilized in RT-PCR 
flank the intronic region the SNP of interest is located. A single product was identified 
indicating no splice variants present due to genotype; however, this does not negate the 
possibility of alternative spliced forms of DRD2 present in cattle. Alternate splicing of 
DRD2 has been reported in rats and humans, resulting in long and short forms of the 
receptor; however, both forms are functionally coupled to G-proteins and can suppress 
PRL expression (Dal Toso et al., 1989; McChesney et al., 1991).  
These data show that EA consumption could impact male reproductive physiology 
by binding to DRD2 receptor in the testis and accessory glands could impact reproduction. 
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This binding could alter spermatogenesis, sperm maturation or the makeup of seminal fluid 
impacting sperm physiology and subsequent fertility. Further, if the toxin is present in 
seminal fluid, sperm physiology could be altered through binding to the DRD2 receptor or 
other receptor types which may be present and are capable of binding EA.  Dopamine 
receptors have been well established in male physiology in both rats and humans. 
Dopamine type-2 receptor agonists and antagonists have been heavily studied linking 
DRD2 to initiation of ejaculation (Ferrari et al., 1994; Peeters et al., 2008; Stafford et al., 
2006). However, this retrospective study would indicate little if any effect on bovine male 
growth and semen quality at time of collection due to EA consumption. In contrast, two 
previous studies show an impact of EA consumption on the ability of bovine semen to 
survive normal extension and freezing procedures (Burnett et al., 2017; Pratt et al., 2015), 
supporting the observation of Gallagher and Senger (1989), showing that incubation of 
sperm with dopamine agonists decrease sperm freezing potential. 
Genotyping was originally attempted by nested PCR. In brief, end-point PCR was 
performed for the F1-R793 DRD2 region (Campbell et al., 2014). The resulting products 
were subjected to nested PCR with primers flanking the SNP site (Campbell et al., 2014) 
for genotype (AA, AG, GG) on either the forward or reverse primer. The specific forward 
and reverse primers were run with primers flanking either the end of the sequence at 793 
bp or the beginning of the sequence, 1bp, respectivley. The resulting products should have 
amplified only for the specific genotype, but when run with known genotyped animals, 
results were inconclusive. The RFLP method was then conducted and the resulting 
products were subjected to dideoxysequencing along with subcloned samples of known 
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DRD2 genotype to assess issues with specific amplification of the prior methods. Results 
were again inconclusive, with clones of known genotype and resulting products of RFLP 
unable to read ‘G’ in all samples sequenced, suggesting the polymerase may be unable to 
read through the ‘G’ ‘C’ rich region of this particular site. The custom Taqman geontyping 
assay was utilized to compare to RFLP methods. Both produced nearly identical results in 
known genotyped animals, with 3 animals differing between methods, accounting for a 3.4 
% error rate among calls. These three samples may have differed due to possible 
contamination issues, with genotypes all resulting in AA in the taqman genotyping assay. 
These samples were limiting and we were unable to genotype them again. An attempt to 
isolate DNA from urine samples from these same animals was made but was unsuccessful. 
The DNA isolated from urine never resulted in quality template due to contaminants and 
sediment in the urine. However, the error in genotypic calls is extremely low and does not 
directly impact the overall distribution within the study. This comparison of Taqman 
methods to RFLP conclude both methods’ reliability for use in further studies for 
genotyping.  
Body weight and BCS in relation to period are in agreeance with our lab’s previous 
work in which BW and BCS were unaffected by treatment alone, with BCS effected by 
day (Stowe et al., 2013). When examining a subset of bulls in 2011, it was found that SC 
was decreased at the end of a 126 d study when bulls were consuming a high concentration 
of EA; however, considering data across all four years SC were not affected by treatment. 
A lack of effect on SC may be due to the duration of the periods analyzed, as this current 
study only looked out to 84 days whereas Stowe et al. (2013) extended their analysis to 
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126 days. A change in SC was observed across all bulls due to period, with prolonged time 
on study resulting in a higher SC. However, these two studies differ in treatment delivery, 
with the current study grazing, with the exception of year 2011, and the previous study by 
Stowe et al. (2013) fed a concentrate diet throughout. Moreover, the current observations 
on SC are consistent with conclusions by Looper et al. (2009) and Schuenemann et al. 
(2005) who also report no change in SC due to EA exposure.  
The current observations agree with the consensus of the literature to date in which 
animals grazing a dopamine agonist, experience a decrease in circulating serum PRL 
concentrations (Porter et al., 1992; Pratt et al., 2015; Schillo et al., 1988). However, the 
conclusions on serum PRL concentration are contradictory to findings by Campbell et al. 
(2014) who observed differences in serum PRL concentrations according to DRD2 
genotype. In the current study, PRL levels remained consistent across DRD2 genotypes. 
Campbell et al. (2014) observed a correlation with serum PRL concentrations with GG 
genotypes experiencing decrease in PRL and steers with the AA genotype experiencing 
higher PRL concentration when grazing E+ in May. However, they did not observe this 
same effect consistently across all months that animals were on treatment. Their results for 
the month of June, although attributed to heat overriding genotypic advantage, more 
closely align with our current findings in which genotype had no effect on PRL 
concentrations. Moreover, our study assessed effect of period on cattle grazing E+ and E- 
spanning from April to August or February to August. Period was found to have no 
significant effect on PRL serum concentrations. 
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Previous data are contradictory on semen quality regarding bull exposure to EA. 
Ergot alkaloids have been shown to impact semen quality, with previous studies reporting 
decreased semen concentration (Pratt et al., 2015), motility and morphology (Looper et al., 
2009; Pratt et al., 2015) while others have reported no effects (Schuenemann et al., 2005; 
Stowe et al., 2013). Our current findings support these later observations, with no effect on 
motility, concentration or morphology due to treatment or period. Further, our results 
conclude that DRD2 genotype has no effect on semen quality. Interestingly, velocity was 
impacted by period, with bulls longer on study exhibiting an increase in semen velocity. 
This has been observed in our previous findings for bulls grazing a dopamine agonist in 
which velocity was effected by day (Burnett et al., 2017) and is most likely attributed to 
increasing bull age and/or seasonal change from winter to spring temperatures. These 
results are contradictory to what is seen in hyperprolactinemia patients, in which velocity 
is increased with hightened circulating serum PRL concetrations (Panidis et al., 1997). 
Summary 
Results from this research indicate that DRD2 SNP genotype (Campbell et al., 
2014) does not play a role in male physiology pertaining to semen quality, growth, or 
circulating levels of serum PRL. These data are however, in agreement with a treatment 
effect on serum PRL concentrations in bulls grazing EA. However, these results are 
contradictory to previous findings on this SNP that did find an association of serum PRL 
concentrations to SNP genotype in steers (Campbell et al., 2014). The treatment effect 
observed with serum PRL concentrations decreased in bulls exposed to a dopamine agonist 
indicated that the SNP did not alter structure or function of DRD2. No differences in growth 
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or semen quality due to SNP genotype also indicate that the SNP has no systemic effects. 
The SNP is located within a non-coding region of the DRD2 gene, so the current 
observations presented here are plausible.  
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Figure 2.1 Immunohistochemical detection and end-point PCR of DRD2 in testis and 
epididymis.  
 Panels are labeled at the top left in bold. Panel (A) Immunohistochemistry of 
DRD2:  Panels (A), (C) and (E) are negative controls for the primary Ab and panels (B), 
(D) and (F) were incubated with anti-DRD2 Ab. Dopamine receptor type-2 staining is 
shown in red. Slides were counterstained with DAPI (blue) for visualization of the nuclei. 
Both stains are indicated by white arrows in panel (D) with staining for DRD2 and DAPI 
indicated by arrows labeled 1 and 2, respectively. Tissue types are as follows: panels (A) 
and (B) are testis, panels (C) and (D) are epididymis, panels (E) and (F) are sperm cells. 
All images were taken at 40x magnification. Ab, antibody; DRD2, Dopamine type-2 
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receptor. Panel (B) End-point PCR: An 87 bp amplicon for DRD2 mRNA expression is 
shown in testis and epididymis. MW, molecular weight ladder; DRD2, Dopamine type-2 
receptor. 
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Figure 2.2 Treatment effect on prolactin serum concentrations of bulls grazing a 
forage containing (E+) or lacking (E-) a dopamine agonist.  
 Bulls on treatment showed overall lower serum concentrations of PRL than E- 
bulls. Different letters indicate significance (P = 0.02) due to treatment. 
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Figure 2.3 Comparison in genotype calls for RFLP and the custom Taqman 
genotyping assays. 
 Genotyping of the DRD2 SNP by Taqman and restriction fragment length 
polymorphism methods resulted in 96.6% identical calls between both methods. 
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Figure 2.4 A representative sample of bulls analyzed by RFLP and Taqman analysis 
for DRD2 genotypes.  
 Panels are denoted on the top left in bold. Panel (A) RFLP analysis: molecular 
weight marker is on the left and product sizes are on the right. Bull IDs are below each 
lane.  All products were incubated in the absence (U) or presence (C) of TfiI restriction 
enzyme.  A single band present at 793 bp indicates a lack of the TfiI restriction site and is 
genotyped as GG. The presence of two bands at 532 and 261 indicate homozygous for the 
TFiI site and genotyped as AA.  The presence of all three bands are genotyped as AG.  
Panel (B) Taqman analysis: The allelic discrimination plot from the custom Taqman 
genotyping assay for the DRD2 SNP region contains a shape, each representative of a 
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single animal with each cluster represented by a different color, representing a genotype. 
Plots are represented as relative fluorescence units (RFU) for each allele. Allele 1 
representing RFU for ‘G’ on the horizontal axis and Allele 2 representing ‘A’ on the 
vertical axis. Genotypes are represented as the following: Orange circles, GG; Green 
triangles, AG; Blue squares, AA; Black dot, non-template control (NTC). 
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Parameter d 0 d 21-28 d 42-56 d 84 P-Value 
Body weight (BW) (kg) 508.56 ± 11.8c 520.90 ± 11.8bc 534.6 ± 11.8b 551.8 ± 12.3a < 0.001 
Scrotal Circumference 
(SC) 35.4 ± 0.41
c 35.8 ± 0.41bc 36.5 ± 0.41a 36.3 ± 0.44ab 0.0053 
Body Condition (BCS) 5.9 ± 0.21a 5.5 ± 0.21b 5.5 ± 0.21b 5.6 ± 0.22b 0.0009 
Table	2.1.	Mean	body	weight,	body	condition	and	scrotal	circumference	of	bulls	grazing	ergot	alkaloids	(E+)	
or	a	diet	lacking	ergot	alkaloids	(E-)	up	to	84	days. 
a-c	Means	within	the	same	row	possessing	a	different	superscript	lowercase	letter	differ	due	to	day.	 
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Parameter d 0 d 21-28 d 42-56 d 84 P-Value 
Concentration (million/mL) 383.2 ± 54.9a 377 ± 54.6a 435.3 ± 56.5a 448.5 ± 59.7a 0.42 
PROG Motility (%) 66.5 ± 2.96a 71.5 ± 2.95a 71.6 ± 3.13a 72.9 ±3.49a 0.35 
Motility (%) 76.5 ± 2.49a 82.1 ±2.46a 82.3 ± 2.74a 84.2 ± 3.13a 0.27 
Normal Morphology (%) 85.6 ± 4.91a 84.9 ± 4.73a 84.2 ± 5.00a 92.2 ± 5.42a 0.55 
Motile sperm cells (x 10^6) 304.1 ± 34.9a 298.0 ± 34.7a 351.2 ± 36.2a 345.7 ± 38.8a 0.31 
Velocity (¥/sec) 51.5 ± 3.77b 56.2 ± 3.74ab 62.8 ± 3.96a 63.6 ± 4.39a 0.04 
Total number sperm cells (10^6) 2.08 ±  0.639a 2.65 ± 0.637a 3.11 ± 0.654a 2.47 ± 0.682a 0.24 
Total Motile Sperm (million/mL) 1.68 ± 0.423a 2.04 ± 0.421a 2.42 ± 0.432a 1.90 ± .452a 0.17 
Total Progressive sperm cells 
(million/mL) 
1.49 ± 0.348a 1.80 ± 0.346a 2.15 ± 0.356a 1.64 ± 0.376a 0.16 
Table	2.2.	Mean	semen	characteristics	of	bulls	grazing	ergot	alkaloids	(E+)	or	a	diet	lacking	ergot	
alkaloids	(E-)	up	to	84	days. 
a-b	Means	within	the	same	row	possessing	a	different	superscript	lowercase	letter	differ	due	to	day. 
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CHAPTER THREE 
EVALUATION OF AN INTRONIC BOVINE DRD2 SNP 
ASSOCIATION TO PROLACTIN PROTEIN EXPRESSION 
IN BOVINE REPRODUCTIVE AND ANTERIOR PITUITARY TISSUES 
 
Abstract 
 Detrimental effects to male reproductive physiology have been observed due to 
changes in prolactin (PRL) serum concentration. Regulation of PRL by dopamine binding 
to the dopamine type-2 receptor (DRD2) is well defined and associations between male 
physiology and single nucleotide polymorphisms (SNPs) within the DRD2 gene have been 
observed. Association of a bovine DRD2 SNP with serum PRL concentrations has been 
previously reported in steers. In contrast, the DRD2 SNP was not associated with PRL 
serum concentration, growth traits, or semen quality in bulls, warranting further 
investigation on the SNP genotypic effects on PRL production and secretion in bulls. The 
objective of the current study was to evaluate association of a DRD2 SNP to PRL protein 
expression in bull reproductive and anterior pituitary tissues. Testis and epididymis were 
collected from bulls grazing a forage containing or lacking a dopamine agonist at the end 
of a 126 d study (n = 14) and bovine pituitaries (n = 587) were collected from a local 
abattoir. Prolactin protein expression was assessed in all tissues by western blotting; 
however, PRL protein was below detection range in reproductive tissues but was present 
in pituitary, therefore experiments continued in pituitary. Sex determination of pituitaries 
was performed by duplex PCR and Southern blotting methods and genotyping was 
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performed by restriction fragment length polymorphism (RFLP). The DRD2 SNP region 
was amplified followed by digestion with a Tfil enzyme, producing 3,2, or 1 band (AG, 
AA, GG, respectively). Pituitary genotype population was 17.4% AA, 63% AG, and 19.6% 
GG. Protein expression was assessed by slot blot and densitometry analysis, normalized to 
GAPDH expression (n = 92). Prolactin protein expression in the pituitary was similar 
across genotype (P = 0.23) and agrees with previous observations on this SNP indicating 
no genotypic effect on growth or semen quality traits in bulls.  
Introduction 
 Prolactin (PRL) is a 22kDa peptide involved in over 300 diverse biological 
functions (Freeman et al., 2000). Prolactin is produced by lactotrophs in the anterior 
pituitary, and it’s release and synthesis is negatively regulated via tonic inhibition by 
binding of dopamine to the dopamine type-2 receptor (DRD2) (Ben-Jonathan et al., 2001). 
Once released, PRL binds to its receptor, activating the Janus Kinase-Signal transducers 
and activators of transcription (JAK-STAT) pathway (Campbell et al., 1994). 
Phosphorylation of JAK2 triggers the association and phosphorylation of STAT5 (Ihle et 
al., 1996). Phosphorylation of STAT1, STAT3, and STAT 5 have been observed in PRL 
signaling through PRLR; however, the predominant transcription factor involved is STAT5 
(Gouilleux et al., 1994; Lebrun et al., 1995). Transcription factor STATs form heterodimers 
and translocate to the nucleus to stimulate gene transcription by binding to defined nucleic 
acid sequences within promoter regions of genes (Ihle et al., 1996). The main source of 
inhibition of PRL is by suppression of adenylyl cyclase to inhibit PRL production. Cells 
treated with a dopamine agonist exhibit reduced PRL transcription which can be rescued 
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by treatment with cyclic AMP (Maurer, 1981). More immediately, upon binding of 
dopamine to DRD2 on lactotrophs, a rapid decrease in intracellular calcium occurs 
suppressing the release of PRL from secretory granules (Ben-Jonathan et al., 2001).   
Cattle consuming dopamine agonists such as ergot alkaloids, which bind to DRD2 
receptors, exhibiting reduced circulating serum concentrations of PRL (Schillo et al., 1988; 
Strickland et al., 2011; Pratt et al., 2015). Further, decreased semen motility and 
morphology (Looper et al., 2009; Pratt et al., 2014) have also been reported in these bulls, 
supporting observation in humans where hypoprolactenemia is associated with semen 
motility (Gonzales, et al., 1989). In contrast, hyperprolactinemia in human males is 
associated with infertility (Segal et al., 1976) and impotence (Segal et al., 1979). Further 
supporting effects of PRL on male reproductive physiology, early PRLR ablation 
experiments in mice resulted in infertile males (Ormandy et al., 1997). Unfortunately, later 
data using knockout models did not support these observations and mechanisms in which 
reproductive male physiology is impacted by PRL, whether through a direct or indirect 
mechanism, remain unclear.  
The PRL signaling pathway has been implicated in effects on reproductive 
efficiency of several species and may provide a route for indirect effects on mammalian 
reproduction (Segal et al., 1979; Gonzales et al., 1989; Ormandy et al., 1997). Some of 
these indirect effects may be explained by the presence of single nucleotide polymorphisms 
reported to be present in the bovine DRD2 (Campbell et al., 2014), PRL (Looper et al., 
2010), PRLR (Ormandy et al., 1997), and STAT5 (Brym et al., 2004; Flisikowski et al., 
2003) genes. The SNPs reported for these four genes result in over 2,000 possible genetic 
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combinations that could impact PRL signaling and therefore indirectly affect mammalian 
reproductive physiology. Evidence for impact on male physiology due to dopaminergic 
SNPs exist. A polymorphism in DRD2 exon 7 in which a cytosine to thymine substitution 
at nucleotide 3420 results in homozygous genotype is highly association with 
hyperprolactinemia in male patients (Hansen et al., 2005). Further, a cytosine insertion in 
the DRD2 gene has been shown to impact PRL secretion as measured by increasing blood 
serum concentrations leading to erectile dysfunction (Zhang et al., 2011). Recently in 
cattle, a SNP has been identified that exists within the DRD2 gene located on bovine 
Chromosome 15 at position 404365, on the third intron. The SNP consists of a base 
substitution between adenine and guanine (Campbell et al., 2014). The bovine DRD2 SNP 
yields three genotypes when digested with Tfi I, AA (532 and 261bp), AG (793, 532 and 
261bp), and GG (793bp) (Campbell et al., 2014). Similarly, to humans, the DRD2 SNP 
genotype homozygous ‘GG’ genotype is associated with decreased serum prolactin 
concentrations in cattle exposed to a dopamine agonist (Campbell et al., 2014). The bovine 
DRD2 SNP is located within a non-coding region, and therefore would not affect protein 
structure/function however, its effects on PRL release and synthesis could be due to effects 
on gene expression. Contrary to the prior findings, recent research indicates that genotype 
does not impact male physiology, having little or no effect on semen quality parameters or 
prolactin serum concentrations in bulls grazing a dopamine agonist (DeCarlo et al., 2019). 
This research aims to elucidate the role of the DRD2 SNP (Campbell et al., 2014) on PRL 
protein expression in the pituitary. 
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Materials and Methods 
Treatment and tissue collection 
Treatment of the yearling beef bulls in which testis and epididymis tissues were 
collected are described by Stowe et al. (2013). In brief, bulls were fed a ration that included 
or excluded ergot alkaloids at 0.8µg/g dry matter, then allowed to graze for a total period 
of 126 d. Testes and epididymides were collected 60 days after removal from ergot 
alkaloids. 
Bovine pituitaries (n = 587) were collected at local abattoir, the anterior and 
posterior lobes were carefully excised, placed into a cryotube, flash frozen in liquid N2 and 
stored at -80 °C until analysis. Bovine ovaries (n = 5) were also collected from the abattoir, 
transported on ice to the laboratory, and frozen at -80°C until used for further analysis.   
RNA isolation and RT-PCR 
 Total RNA was isolated from anterior pituitary tissues using the TriZol isolation 
methods (Invitrogen, Carlsbad, CA, USA) and isolated from testis and epididymis tissue 
using the mirVana mRNA isolation kit (Ambion, Austin, Texas, USA). Samples were 
subjected to nanodrop 1000 spectrophotometry (Thermo Fisher Scientific, Waltham, MA, 
USA) to assess concentration and purity by A260:A280 ratio. Quality of RNA samples 
were confirmed through Agilent 2100 nano chip assay (Agilent Technologies, Santa Clara, 
CA, USA) to obtain a RIN value. Only samples that possessed a RIN of ³ 7 were utilized 
for analysis. 
 Complimentary DNA was generated using qScript cDNA Supermix (Quantabio, 
Beverly, MA, USA). Primers for PRL (NM_173953.2) flanking nucleotide positions 146-
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431, TH (NM_173884.2) (an indirect measurement of dopamine synthesis) flanking 
nucleotide positions 1263-1381, DRD2 (NM_174043.2) flanking nucleotide positions 510-
597 of the mRNA DRD2 sequence, and PRLR (L02549) flanking nucleotide positions 
1107-1216 were generated through IDT primer quest tool (Integrated DNA technologies, 
Coralville, IA) for use in polymerase chain reaction (PCR) (Table 3.1). End-point PCR was 
performed utilizing the following reaction conditions: denaturation at 95° C for 2 min 
followed by 35 cycles at 94° C for 30 sec, annealing 30 sec (PRL, 60° C; DRD2, 52° C; 
TH, 52° C; PRLR, 55° C) and 72° C extension for 30 sec followed by 72° C for 5 min and 
a 4° C hold. Slab gel electrophoresis was performed and the resulting products were 
visualized on a 1.5% agarose gel.  
 To further validate identity of the products, cDNA from testis and epididymis were 
ligated into a pDrive cloning vector overnight at 4° C (Qiagen PCR Plus Cloning kit, 
Hilden, Germany). Ligations were used to transform competent E. coli (EZ competent; 
Qiagen, Hilden, Germany). Resulting transformations were plated on LB agar plates 
containing 100 µg/ml Ampicillin and IPTG/Xgal and allowed to incubate overnight at 37° 
C for blue/white screening. Subsequent colonies were selected from each plate for each 
respective insert, and were propagated through inoculation of LB broth, incubated 
overnight, shaking to aerate at 250 rpm at 37° C. Plasmid DNA was purified using Wizard 
mini-prep plus (Promega, Madison, WI), digested with EcoR1 (Promega, Madison, WI, 
USA) and products of the expected sizes were subjected to dideoxysequencing. 
DNA Isolation 
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Isolations of genomic DNA were performed according to Current Protocols in 
Molecular Biology (Wiley and Sons, Inc., 1998). Posterior pituitary lobe tissues (200 mg) 
and ovary (50 mg) were homogenized directly in DNA lysis buffer (100 mM NaCl, 10 mM 
TrisCl pH 8, 25 mM EDTA pH8, 0.5 % SDS, 0.1 mg/ml proteinase K) (n = 587). 
Phenol:chloroform:isoamyl alcohol (25:24:1; pH 8) were added to the homogenized 
sample, equal to the volume of the lysate. Samples were vortexed for 1 min and centrifuged 
at 1,700 x g for 10 min at RT. The aqueous layer was carefully aspirated and put into a 
sterile tube, followed by addition of 0.5 volume of 7.5 M ammonium acetate and 2 vol of 
100 % ethanol relative to the aqueous layer volume. Resulting precipitated DNA was 
pelleted at 1700 x g for 2 min at RT and DNA pellet saved and the supernatant decanted. 
The DNA pellet was washed in 70 % ethanol and allowed to dry for 15 min followed by 
resuspension in 100 µl of nuclease free water. Samples were heated at 65° C for 30 min 
and then stored at 4° C until further analysis of sex and genotype. Isolated DNA was 
evaluated for concentration and nucleic acid to protein ratio (260/280) by 
spectrophotometry (Nanodrop 1000; Thermofisher). 
Sex Determination 
 Sex was determined (n = 587) utilizing a duplex PCR method described by Curry 
et al. (2008) and Southern blotting techniques. In short, 2 ng of DNA was amplified in a 
25 µl PCR reaction (GoTaq Green; Promega, Madison, WI, USA) including 10 µl of Go-
taq, 1 µl of each β-actin primer and 2 µl of each SRY primer. Controls, including a 
known male sample (testis) and a known female sample (ovary) were also subjected to 
duplex PCR amplification. Single products of β-actin and SRY generated from 2ng of 
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purified plasmid DNA products, verified by dideoxysequencing served as additional 
controls on each blot. Reaction conditions consisted of 95° C for 2 min, 94° C for 30 sec, 
annealing at 60° C for 30 sec and extension at 72° C for 30 sec for a total of 35 cycles, 
followed by 72° C for 5 min and a 4° C hold. Reactions were treated according to Curry 
and others (2008). In brief, samples were denatured by addition of NaOH (0.1 vol) and 
heated at 37° C for 5 min followed by addition of SSPE (3 M NaCl, 0.2 M NaH2PO4, 
0.02 M EDTA) at a final 6X concentration. Reactions were blotted using a dot blot 
manifold. Nylon membrane (Biobond-Plus Nylon Membrane; Sigma, St. Louis, MO, 
USA) was soaked in nuclease free water for 10 min prior to assembling the blot manifold. 
The manifold was set up with the pre-soaked nylon membrane placed on top of two 
Whattman filter papers. Each well was washed initially with 300 µl nuclease-free water 
followed by blotting of products. After addition of samples to the membrane, the wells 
were washed with 300 µl 0.4 M NaOH. The manifold was disassembled and the resulting 
blot was rinsed briefly in 2X SSC (20X solution; 0.3 M sodium citrate, 3 M NaCl, pH 
7.0) and allowed to dry completely before crosslinking at 120 cm2/j for 1 min (XL-1000 
UV crosslinker). 
Amplification of single, β-actin and SRY products were generated using 2 ng 
genomic DNA (GoTaq Green; Promega, Madison, WI, USA). Reaction conditions are as 
described above. Purified products were ligated into pDrive cloning vector (Qiagen PCR 
Plus Cloning kit, Hilden, Germany), subcloned, and resulting transformations plated. 
Vectors containing the inserts of interest were propagated and plasmids isolated. Inserts 
were amplified using end-point PCR for β-actin and SRY (Genewiz, Plainfield, NJ, USA). 
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Resulting PCR products were purified (Wizard SV Gel and PCR Clean-Up System, 
Promega, Madison, WI, USA) and subjected to spectrophotometry to assess concentration 
and quality by 260/280 nucleic acid to protein ratio. Samples with a ratio of 1.8 - 2.0 were 
utilized for generation of probes. Labeling was then carried out by random prime labeling 
(North2South Biotin Random Prime DNA Labeling Kit, Thermo Fisher Scientific, 
Waltham, MA, USA). Probes were generated using 200 ng of purified PCR products in a 
final volume of 24 µl with nuclease-free water followed by addition of 10 µl 
heptanucleotide mix. Samples were denatured by boiling for 5 min and quickly placed in a 
methanol dry ice bath. The samples were thawed on ice followed by the addition of 10 µl 
of 5X dNTP mix, 5 µl of 10X reaction buffer, and 1 µl Klenow fragment for a final volume 
of 50 µl. The samples were then incubated at 37° C for 1 hr following inactivation with 
addition of 2 µl 500 nM EDTA (pH 8.0). Unincorporated nucleotides were removed by 
size exclusion chromatography. Sephadex G50 (1 g) was allowed to swell in approximately 
10 mL phosphate buffered saline (PBS) (1X) at RT overnight. A column was produced 
using a 1 mL syringe with steel wool packed into the bottom measuring to approximately 
0.1 mL on the syringe. The swelled sephadex mixture was loaded into the syringe barrel to 
the top and allowed to drip for 1 hr at RT followed by centrifuging at 2000 x g for 1 min 
at RT to pack the column. The column was placed into a 15 mL conical tube to catch flow-
through and was initially washed with PBS (100 µl) by slow addition to the top of the 
column and centrifugation at 2000 x g for 1 min at RT. The flow through was discarded 
and the column was placed into a new sterile tube. The full volume of the labeled probe 
was then loaded onto the column followed by centrifugation, 2000 x g for 1 min. The flow-
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through was saved and the column was washed once more with 100 µl PBS utilizing the 
same flow-through tube. The resulting flow through was transferred to a new sterile tube 
and subjected to denaturation by boiling for 10 min followed by 5 min incubation on ice. 
Pre-hybridization, hybridization, and chemiluminescent detection were performed 
using the North2South Chemiluminescent Hybridization and Detection Kit (Thermo Fisher 
Scientific, Waltham, MA, USA). Kit contents were allowed to come to RT or incubated at 
37° C until no precipitate existed before use. Pre-hybridization of blots were performed in 
two separate hybridization tubes in a hybridization oven at 55° C (Problot Hybridization 
Oven, Labnet, International) in 10 mL of pre-hybridization buffer for 30 min followed by 
addition of probe, either β-actin or SRY, directly to the buffer for each blot (hybridization 
buffer). Hybridization was carried out overnight at 55° C, rotating.  
 The hybridization buffer was discarded and each blot washed 3X in stringency 
wash buffer at 55° C for 15 min each wash, rotating. The membranes were then blocked 
for 15 min at RT with gentle agitation. Streptavidin was diluted 1:300 in blocking buffer 
and then added to the membrane to incubate again for 15 min at RT with gentle agitation. 
The solution was then decanted and the blots were incubated in substrate equilibration 
buffer for 5 min at RT. The blots were then covered in substrate for 5 min at RT then 
exposed to chemiluminescent detection for 2 min (FluorChem FC2, Alpha Innotech, San 
Leandro, CA, USA). Confirmation of males was performed by densitometry. Samples were 
considered male if they met or exceeded the density of the testis control on each blot. 
Samples that came up inconclusive, in which signal density was just below or between the 
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threshold of background versus male control sample, were blotted an additional time to 
assure accuracy in calls. 
Genotyping 
 Genotyping of male pituitaries (n = 259) were performed according to the 
restriction fragment length polymorphism method described by DeCarlo et al. (2019), with 
modifications. In brief, amplification of the DRD2 region flanking a SNP (A534G) was 
performed (Campbell et al., 2014) with 10 ng starting template genomic DNA (GoTaq 
Green Master Mix, Promega, Madison, WI, USA). Resulting products were digested with 
Tfil enzyme overnight at 37° C (ThermoFisher Scientific). Digested products were 
visualized on a 1.0 % agarose gel. 
SDS-PAGE and western blotting 
Protein extracts were produced from testis, epididymis, ovary, and anterior pituitary 
tissues (100 mg starting material). Samples were homogenized in an ice-cold lysis buffer 
(1X RIPA with 10 µl/mL Protease inhibitor HALT). Protein concentrations were 
determined using the DC protein assay with each sample performed in duplicate (Bio-Rad; 
Hercules, CA). Samples were stored at -20° C until used for further protein analysis.  
Protein extracts of testis, epididymis, ovary, and anterior pituitary were diluted in 
molecular grade water and 2X laemmali buffer with addition of 1/8th volume of beta 
mercaptoethanol to a total mass of 30 µg and 60 µg, for detection of PRL and GAPDH, 
respectively. Samples were denatured for 5 min by boiling and directly chilled on ice for 5 
min. Denatured samples were centrifuged at 13,000 x g for 10 min and loaded onto a 12 % 
mini protean TGX precast polyacrylamide gel at a total volume of 20 µl per well (Bio-Rad; 
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Hercules, CA). Gel electrophoresis was performed at 75 volts for 1 hr and 15 min and 200 
volts for 20 min for GAPDH and PRL, respectively. Proteins were blotted onto a 0.2 µm 
nitrocellulose membrane (Bio-Rad, Hercules, CA, USA) at 100 volts for 1 hr. Transfer of 
proteins was assessed by staining with Ponceau S for 5 min and the polyacrylamide gel 
stained with coimmasse blue overnight. The membrane was allowed to dry overnight at 
RT, protected from light.  
 For the detection of PRL, blotted proteins (30 µg) were blocked in 3.5 % non-fat 
dry milk in a tris-buffered saline buffer with 0.1 % Tween added (TBST) for 1 hr at RT 
with gentle rocking. The membrane was briefly washed in TBST followed by the addition 
of PRL primary antibody diluted to 1:1000 in 1 % non-fat dry milk/ TBST (sc-69874; Santa 
Cruz Biotechnology, Dallas, TX, USA) and allowed to incubate overnight at 4° C. The blot 
was then washed in TBST 3X, 5 min each wash. Secondary antibody was diluted 1:1000 
in TBST (610-703-124; Rockland, Limerick, PA, USA) was added and allowed to incubate 
at RT for 1 hr followed by three washes in TBST, 5 min each. The membrane was laid on 
an acetate sheet and covered in substrate (Clarity Western ECL Substrate; Bio-Rad 
Hercules, CA, USA) for 5 min at RT. The substrate was drained from the blot, covered by 
another piece of acetate, and exposed to chemiluminescent detection for 15 min (Alpha 
Innotech; San Leandro, CA, USA). 
 For the detection of GAPDH, blotted proteins (60 µg) were blocked in 5 % non-fat 
dry milk in TBST for 1 hr at RT with gentle rocking. The membrane was briefly washed 
in TBST followed by the addition of GAPDH primary antibody diluted to 1:1000 in 5 % 
BSA/TBST solution (2118; Cell Signaling Technology, Danvers, MA, USA) and allowed 
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to incubate overnight at 4° C. The membrane was then washed in TBST 3X, 5 min each 
wash. Secondary antibody was diluted 1:1000 in TBST (7074; Cell Signaling Technology, 
Danvers, MA, USA) was added and allowed to incubate at RT for 1 hr followed by three 
washes in TBST, 5 min each. Substrate was added to the blot and after 5 min exposed to 
chemiluminescent detection for 15 min. 
Evaluation of PRL protein expression in bovine pituitary 
Linear range of detection was determined by blotting increasing mass of protein by 
slot blot manifold followed by exposures at varying times by chemiluminescent detection. 
Blotting by slot blot manifold was performed using 6 size No. 1 Whattman filter papers 
topped with a 0.2 µm nitrocellulose membrane. The manifold was sealed and each well 
washed with 200 µl of nuclease-free water followed by application of vacuum. Anterior 
pituitary protein (AA n = 16; AG n = 58; GG n = 18) (10 µg) was then blotted followed by 
an additional wash with deionized water. Blots were then stained with Ponceau S (Sigma-
Aldrich, St. Louis, MO, USA) to assess transfer, rinsed with TBST briefly and treated with 
hydrogen peroxide (3 %) at 37° C for 10 min with gentle agitation to remove peroxidase 
activity. Blots were then placed in non-fat dry milk blocking solution and immune-
detection carried out as described above for GAPDH. Chemiluminescent detection was 
performed using an Fluorchem FC2 (alpha innotech, San Leandro, CA, USA) for a 15 min 
exposure. Blots were then washed in TBST for 5 min and stripped using two washes of 
glycine (400nm, pH 2.5) for 5 min each at RT, followed by two PBS washes and a TBST 
wash for 5 min each. Immuno-detection for PRL was then carried out according to the 
protocol outlined above. Membranes were again exposed at 15 min for chemiluminescent 
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detection. Total protein on each blot was also evaluated by densitometry utilizing Ponceau 
S stain. Inter- and intra-assay coefficients were 7.4 % and 6.9 %, respectively. 
Statistical analysis 
Densitometry data for PRL protein expression was normalized to a GAPDH 
housekeeping protein density as follows. Background subtraction was applied to each 
GAPDH and PRL sample densities for all samples in duplicate. Blot normalization factors 
were calculated for each blot (highest GAPDH expression value on blot/ GAPDH signal 
of each individual sample). The density (after background subtraction) of each sample for 
PRL signal was then divided by the blot normalization factor to obtain relative protein 
expression. Analysis of Variance was performed for all densitometry data to assess DRD2 
genotype impact on pituitary PRL protein expression. The model for the Analysis of 
Variance included genotype as a fixed effect. Significance was set at (P < 0.05) and all 
statistical analysis was performed using JMP software (SAS Institute Inc.). 
Results 
Messenger RNA and protein expression  
The messages for PRL and TH were present in testis and epididymis (figure 3.1). 
Previously published work also confirms the presence of DRD2 in testis and epididymis 
(DeCarlo et al., 2019). Further work to assess protein expression of PRL in testis and 
epididymis by western blotting was unsuccessful as the protein concentrations may be 
below detection range in these tissues. Prolactin (~22kDa) was present in pituitary as 
expected and therefore, experiments continued in bovine anterior pituitary (Figure 3.2). 
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Amplifications of PRL, DRD2, PRLR, and TH were performed in anterior pituitary with 
the message for all present (Figure 3.3).  
Sexing and genotypic distribution 
 Sexing by PCR and Southern blot revealed 55.9% females and 44.1% males. An 
example of dot blots probed with SRY and β-actin are shown in Figure 3.4. Genotyping 
was performed by RFLP procedures. Genotypic distribution was determined to be AA 
17.4%, AG 63%, and GG 19.6%. 
Prolactin protein expression in anterior pituitaries 
Prolactin protein expression was evaluated across genotype by slot blot and 
immunodetection procedures. Densitometry analysis revealed no differences in PRL 
protein expression due to DRD2 genotype (P = 0.23) (Figure 3.5). 
Discussion 
Initial goals of these experiments were to assess if the message for PRL and its 
regulatory system (DRD2 and its rate-limiting enzyme tyrosine hydroxylase) were present 
in male reproductive tissues. Our findings indicate that the message for PRL and TH are 
present in bovine testis and epididymis. These findings agree with other species in which 
PRL has been identified in semen, male accessory glands (Nevalainen et al., 1997; Sanford 
and Baker, 2010) and germ cells (Pratt et al. 2014; Sheth et al., 1975). Dopamine type-2 
receptor has also been identified in male germ cells (Otth et al., 2007; Ramirez et al., 2009) 
as well as in the testes of mice (Gonzalez et al., 2015) and most recently in cattle testes, 
epididymides, and germ cells (DeCarlo et al., 2019).  
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 We were not able to detect PRL in any testis, epididymis or ovary by western 
blotting. Given that the message for PRL is present in testis and epididymis, it is possible 
that PRL protein expression was just below the detection range for western blotting. Bovine 
anterior pituitary, the main site of production of PRL, did reveal ~22 kDa band as expected. 
without possible detection of PRL protein in testis and epididymis, experiments continued 
in the pituitary to examine possible genotypic effects of the DRD2 SNP previously 
associated with decreased serum PRL concentrations.  
 Slot blotting of anterior pituitary protein was performed to assess PRL protein 
expression across DRD2 SNP genotype. Original experiments to assess antibody 
specificity revealed evidence of high peroxidase activity in bovine anterior pituitary 
protein. To combat this issue, membranes with slot blotted anterior pituitary protein were 
treated with a 3% hydrogen peroxide solution prior to immunodetection procedures 
(Figure A.1). Experiments to determine optimal time, temperature, and hydrogen 
peroxide concentration to eliminate peroxidase activity were performed (Appendix A). 
 Sex determination of pituitaries were performed by duplex PCR and Southern 
blotting techniques. Original DNA isolations were performed using only 50 mg of posterior 
pituitary tissue starting material and a simple phenol chloroform extraction method that 
resulted in genomic DNA isolations containing large quantities of RNA. Increased 
specificity of Southern blotting utilizing hybridization to combat this issue. Isolations were 
then performed with a much higher, 200 mg of tissue for genotyping. The RFLP 
genotyping protocol was adapted from the previously used protocol (DeCarlo et al., 2019) 
in order to eliminate the need for the PCR purification step prior to digestion. Experiments 
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were performed with known genotyped samples to ensure enzyme digestion accuracy (data 
not shown) and an overnight digestion was able to allow for immediate digestion after 
amplification of the SNP sequence, without PCR clean-up.  
 The DRD2 SNP (A534G) is located in a non-coding region and therefore is not 
expected to affect protein folding or structure but possibly could affect gene expression 
within the PRL pathway. These data indicate no association of DRD2 SNP genotype to 
PRL protein expression in the bovine anterior pituitary. Previous studies on this DRD2 
SNP showed no changes in serum PRL concentrations observed due to SNP genotype 
(DeCarlo et al., 2019). These two observations would indicate that the reported bovine 
DRD2 SNP does not affect the production or release of PRL. The genotypic distribution 
presented here is nearly identical to previous reported distributions for this DRD2 SNP 
(Meyer et al., 2016; DeCarlo et al., 2019) but are contradictory to Campbell et al. (2014) 
who observed a genotypic effect on PRL serum concentrations. The same study also 
reported a genotypic effect associated with hair coat score, which has been linked to PRL 
levels in cattle (Campbell et al., 2014); however, Meyer and others (2016) only observed a 
tendency for this association, although they did not directly measure serum PRL 
concentrations. Observations from this current study agree with findings by Meyer and 
others (2016) in which no change in PRL protein was observed according to genotype. 
Further, genotyping methods used in this study have been validated by a second genotyping 
method previously (DeCarlo et al., 2019), while no validation was used for Campbell and 
others (2014). The DRD2 SNP examined here is located in a non-coding region and 
therefore it is not surprising there was no change in PRL protein expression due to 
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genotype. Many SNPs within other genes affecting the PRL signaling pathway exist (Brym 
et al., 2005; Looper et al., 2010) and may provide more informative avenues to explore 
when assessing SNP genotypic effects on PRL synthesis and secretion. 
Summary 
In summary, the message for PRL, TH, and DRD2 are present in bovine testis, 
epididymis, and pituitary. The message for DRD2 has previously been reported in testis 
and epididymis (DeCarlo et al., 2019). The presence of PRL protein was observed in 
pituitary protein extracts and was not detectable in testis, epididymis or ovary samples. 
These data indicate that PRL protein expression may be lower than what is possible to 
detect by western blotting in male reproductive tissues. Experiments continued at the 
source of PRL production, the pituitary.  
Genotyping ratios were extremely similar to what has previously been reported for 
this SNP (Meyer et al., 2016; DeCarlo et al., 2019) and for what is closest to a normal, 
random distribution (25:50:25). Further investigation of relative protein expression across 
genotype in the pituitary revealed no differences due to DRD2 genotype. These data agree 
with previous findings from this laboratory in which this DRD2 SNP had no effect on PRL 
serum concentrations and furthermore, no effects on growth, reproduction, and semen 
characteristics (DeCarlo et al., 2019). These data are contradictory to what has been 
previously reported on this DRD2 SNP, which indicate a genotype association to PRL 
serum concentrations (Campbell et al., 2014). This DRD2 SNP is located within an intron 
and does not likely affect protein structure but could affect gene expression; however, these 
data suggest no association between protein expression to the intronic DRD2 SNP.  
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Figure 3.1 Polymerase chain reactions were performed to assess the presence of PRL (A) and TH (B) 
in bovine male reproductive tissues.  
 Products revealed appropriate size bands at 285 bp and 118 bp for PRL and TH, respectively. Lanes 
are as follows: 100bp ladder (L), no template control (H2O), PRL products in testis (T) and in Epididymis 
(E). (B) Bovine PRL and TH cDNA clones produced from the testis and epididymis were subjected to 
dideoxysequencing and aligned to the Bos Taurus PRL mRNA (NM_173953.2) and TH (NM_ 173884.2) 
sequence. Sequence alignments are shown to the right. 
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Figure 3.2 Western blotting analysis of Prolactin (PRL). 
 A band at ~22kDa is present in anterior pituitary (P) but no bands were present in 
testis (T), epididymis (E), or ovary (O). Loading control GAPDH is shown below at ~37 
kDa. Biotinylated ladder is indicated by (L) with band sizes for the ladder shown on the 
left (kDa). Total protein loaded for each PRL and GAPDH was at 30µg and 60µg, 
respectively. 
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Figure 3.3 Polymerase chain reaction for detection of prolactin (PRL), prolactin receptor (PRLR), 
tyrosine hydroxylase (TH) and dopamine receptor type-2 (DRD2) was performed on pituitary cDNA. 
 Ladder (100bp; Promega) is shown in lane 1. Products are as follows: PRL (lane 3), DRD2 (lane 5), 
TH (lane 7), and PRLR (lane 9). Lanes 2,4,6, and 8 are no template controls for each reaction. Sizes are 
indicated for PRL (274bp) and DRD2 (116 bp) on the left and sizes for PRLR (109 bp) and TH (94 bp) are 
indicated on the right. 
 
 
 
 
 
 
274 bp 
116 bp 109 bp 
94 bp 
1    2    3    4    5    6   7    8    9 
 104 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 Southern blotting performed to determine sex of each pituitary sample.  
 Each dot represents a single sample. Probes for each blot are indicated to the right, 
the top blot (SRY) and the bottom blot (bACT). Control samples are noted at the top: 
purified PCR products for bACT (B) and SRY (S) to assess probe specificity; positive 
control female ovary (O) and positive control male testis (T) samples to assess density for 
sex. All samples to the left of controls are pituitary samples of unknown sex. All 
densitometry for unknown samples were compared to testis sample density. Samples were 
considered male if they met or exceeded the density of the testis control. 
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Figure 3.5 Relative PRL protein expression across DRD2 genotype in bovine pituitaries.  
 Relative density of PRL protein expression is shown across DRD2 genotype with error bars 
representative of the standard error of the mean. Slot blots are shown below the bar graph for PRL and 
GAPDH loading control for the respective genotypes indicated above. No differences in relative PRL protein 
expression were observed across DRD2 genotype. 
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OVERALL CONCLUSIONS 
The goals of these experiments were to evaluate an intronic DRD2 SNP, previously 
found to be associated with decreased bovine serum PRL concentrations. Associations 
assessed included DRD2 genotype association with growth traits, semen quality, PRL 
serum concentrations, mRNA expression in male reproductive tissues, and PRL protein 
expression in bovine pituitaries. 
 Evaluation of DRD2 genotype association with growth traits, semen quality, and 
PRL serum concentrations was performed on bulls grazing (E+) or not grazing (E-) a diet 
containing a dopamine agonist. The presence of DRD2 was observed in testis and 
epididymis by immunohistochemistry and polymerase chain reaction. 
Genomic DNA was isolated from semen and used for genotyping by restriction 
fragment length polymorphism and TaqMan techniques. Both techniques were almost 
identical with genotypic frequencies at 18 % AA, 61 % AG, and 21 % GG using RFLP and 
21 % AA, 59 % AG, 20 % GG by the custom Taqman genotyping methods. Results on 
association of DRD2 genotype on serum PRL concentrations is contradictory to what has 
been previously found, in which there was no association found. However, this is consistent 
with a treatment effect in which E+ bulls experience a decrease in PRL serum 
concentrations. No differences were observed in growth traits and semen quality 
parameters due to genotype.  
 The message for DRD2, PRL, and TH was present in the testis, epididymis, and 
pituitary. Further, DRD2 was also present in sperm cells and the message for PRLR was 
also identified in bovine pituitary. Protein expression was evaluated in testis, epididymis, 
 108 
ovary, and pituitary tissues. Western blotting and immunodetection revealed PRL 
expression in the pituitary as expected, but we were unable to detect PRL in reproductive 
tissues, as they may be below detection range. Experiments continued in the pituitary to 
evaluate PRL protein concentrations across genotype. 
 Bovine pituitaries were collected at a local abattoir. A duplex PCR and southern 
blotting technique were utilized to probe for SRY and Beta actin for sexing of samples. 
Subsequent male samples were genotyped by restriction fragment length polymorphism 
method for the DRD2 SNP. Genotypic frequencies were almost identical to our previous 
report at AA 17.4 %, AG 63 %, and GG 19.6 %. Blotting of anterior pituitary protein and 
immunodetection for PRL was performed. No differences in PRL protein expression were 
observed across genotype. These data indicate that the DRD2 SNP previously found to be 
associated with serum PRL concentrations is not associated with PRL protein expression, 
directly at the source of PRL synthesis and secretion, the pituitary.  
 Both studies taken together indicate that we cannot yet negate where effects on 
reproduction are originating. The first study indicates decreased serum PRL concentrations 
in bulls exposed to a dopamine agonist, indicating that DRD2 is functional. Further, 
genotype did not impact PRL serum concentrations indicating that the DRD2 SNP does 
not alter structure or function of DRD2. Dopamine receptors, DRD2 located within 
reproductive tissues and sperm cells and imply that they can be bound by a dopamine 
agonist to elicit effects directly in these tissues to alter processes such as spermatogenesis, 
concentration of semen or maturation; however, the possibility also remains that 
detrimental effects could also be due to overall decreases in serum PRL concentrations. 
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Appendix A 
Treatment for removal of endogenous peroxidase activity 
 Prior to immunodetection, membranes were treated with hydrogen peroxide to 
remove peroxidase activity for all western blot experiments assessing pituitary protein 
expression across genotype (Sennepin et al., 2009). To validate the procedure for removal 
of endogenous peroxidase activity, bovine pituitary proteins were blotted onto a 0.2 µm 
nitrocellulose membrane (Bio-Rad, Hercules, CA, USA) by slot blot manifold in 
increasing mass from 1.2 µg to 40 µg. Membranes were cut into individual strips, pre-wet 
in TBST for 5 min followed by individual treatment of each strip as follows: (1) 
treatment with hydrogen peroxide (3%) for 10 min at 37 °C (2) treatment with hydrogen 
peroxide (3%) for 10 min at 37 °C followed by incubation with secondary antibody only 
(7074; Cell Signaling Technology, Danvers, MA, USA) to assess cross reactivity (H2O2; 
Secondary only) (3) treatment with hydrogen peroxide (3%) for 10 min at 37 °C followed 
by GAPDH immunodetection (H2O2; GAPDH) (4) untreated followed by GAPDH 
immunodetection (Untreated; GAPDH) (2118; Cell Signaling Technology, Danvers, MA, 
USA) (5) Substrate only (Clarity Western ECL Substrate; Bio-Rad Hercules, CA, USA) 
(Substrate only). Blots not treated with hydrogen peroxide were incubated in TBST at 37 
°C with gentle shaking instead. The hydrogen peroxide or TBST wash were decanted and 
the membranes were washed in TBST for 5 min followed by immunodetection 
procedures for GAPDH outlined in chapter III materials and methods. 
 Incubation with only ECL substrate resulted in signal at all pituitary masses, 
indicating endogenous peroxidase activity. Without treatment of hydrogen peroxide, 
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signal of GAPDH is much stronger than with treatment. To validate removal of 
endogenous peroxidase activity, blots were treated with the 3% hydrogen peroxide 
treatment followed by incubation in secondary antibody only. The secondary only blot 
resulted in no signal, indicating that there is no secondary antibody cross reactivity and 
endogenous peroxidase activity was quenched, as incubation in ECL substrate resulted in 
absence of signal. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 112 
 
 
 
Figure A.1 Treatment of hydrogen peroxide for removal of endogenous peroxidase 
activity in bovine anterior pituitary.  
 Bovine pituitary protein blotted in increasing mass (indicated at the top of the 
figure) (B) indicates a blank slot with no protein. Treatments are indicated on the right side 
of the figure: (from top to bottom) (1) treatment with hydrogen peroxide (3%) for 10 min 
at 37 °C (2) treatment with hydrogen peroxide (3%) for 10 min at 37 °C followed by 
incubation with secondary antibody only (7074; Cell Signaling Technology, Danvers, MA, 
USA) to assess cross reactivity (H2O2; Secondary only) (3) treatment with hydrogen 
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peroxide (3%) for 10 min at 37 °C followed by GAPDH immunodetection (H2O2; GAPDH) 
(4) untreated followed by GAPDH immunodetection (Untreated; GAPDH) (5) Substrate 
only. 
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Appendix B 
Methods for detection of single nucleotide polymorphisms 
 Identification of SNPs can be carried out through a variety of methods including, 
array-based hybridization, sequencing, and PCR-based methods. Hybridization techniques 
are utilized in array technology with two of the most popular platforms called Affymetrix 
and Illumina. Affymetrix chips are hybridized with oligonucleotide sequences 
complimentary to the SNP region of interest, with fluorescent probes for each possible 
allele outcome. Fragments of DNA containing the SNP of interest will bind if they are 
similar or an exact match to the hybridized probes on the chip. Signals are obtained from 
these bound fragments, in which those that are completely complimentary will bind with 
higher affinity and therefore obtain a stronger signal then those that bind with decreased 
affinity if they are not completely complimentary. It is also typical to have probes on the 
array that do not contain a complementary sequence that matches the SNP site in order to 
measure background. (LaFramboise, 2009). Illumina utilizes sequences complimentary to 
the adjacent sequence to the SNP of interest and has an extension from that sequence 
containing each possible allele outcome. The oligonucleotides, approximately 50 nt in 
length, are attached to an Illumina bead. The DNA will then bind to its complimentary 
allele and a red or green signal is obtained depending on the allele, with each separate allele 
labeled a specific color. Both chip technologies report over 99.5% accuracy in genotyping 
(LaFramboise, 2009). Either platform can be performed for targeted genotyping across 
many individuals as described above or whole-genome genotyping can be performed to 
discover new variations in DNA of individuals across treatments or phenotype. Software 
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such as SNPtest can be used to determine SNPs of interest pertaining to their association 
with phenotype (Agler et al., 2019). Association of the mutation to phenotype is not always 
based on the smallest P-value, but rather, the abundance in which the mutation occurs in a 
large population that shares a given phenotype (Xu and Taylor, 2009).  
Next generation sequencing (NGS) is performed through multiple steps and relies 
heavily on preparation of a library (Head et al., 2014). Genomic DNA is digested into 
fragments and adaptors are added to the 3’ or 5’ ends for recognition by the primers during 
sequencing. The library is amplified by PCR and sequencing performed by either 
pyrosequencing or sequencing by ligation (SOLiD) (Hurd and Nelson, 2009). 
Pyrosequencing is based on complementary strand synthesis through detection of 
pyrophosphate release after addition of nucleotides to the DNA. Pyrophosphate will only 
be released when the correct base is added onto the template strand and is then converted 
into ATP for the conversion of luciferin to oxyluciferin to produce signal. Light intensity 
corresponds to how many of that correct base is added in succession (Fakruddin et al., 
2013). Sequencing by ligation is performed through emulsion PCR in which a ssDNA 
adaptor is added onto the 3’ end of the sequence that is to be sequenced and all are attached 
to a bead. The beaded sequences are subjected to PCR utilizing primers specific for the 
adaptor sequence and probes that contain fluorescent dyes at the 5’ end of different colors 
corresponding to each base they will recognize. Once the primers bind to the adaptor 
sequence, the probe will bind and DNA ligase with enable joining of the probe to the 
primer. The fluorescent signal is given off by this joining as it will release the fluorescent 
dye that was bound to the probe at the 5’ end. With each round of sequencing, the extension 
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is melted off and the process begins again except with a primer that is 1 less base in length 
each time until the entire sequence is finished (Albrecht et al., 2000). Reads from these 
methods of sequencing can be used to identify variants between groups of samples. There 
are software programs available to assist in variant identification and genotyping of NGS 
reads. Microarrays pose issues with SNP genotyping due to nonspecific binding of similar 
sequences. Signal to noise ratios also become an issue when multiple sequences reach 
either high or low threshold making it difficult to distinguish between groups of those 
highly or lowly expressed SNPs. Moreover, NGS allows for SNP detection through 
genome wide sequencing without a reference genome, whereas microarrays are limited to 
prior knowledge of the genome. Due to preparation of a library and multiples steps for 
performance of NGS, the chance of contamination from one step to another is higher (Hurd 
and Nelson 2009).  
Another form of hybridization detection of SNPs includes a technology called 
fluorescence resonance energy transfer (FRET). This technology utilizes fluorescently 
labeled primers that correspond to each possible allele. When the DNA sequence is 
complimentary to the primer, extension incorporates the labeled probe into the sequence 
and fluorescence is emitted. (Sobrino et al., 2005). This FRET technology has been used 
in conjunction with the exonuclease activity of the Taq polymerase. Taqman assays for 
SNP genotyping require one set of primers that flank the region containing the SNP of 
interest. A set of probes, each corresponding to each allele for the SNP of interest and each 
of a specific fluorophore color, will then hybridize to the DNA if it is the correct base 
match. The fluorophore is attached to the 5’ end and a quencher is attached to the 3’ end. 
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When the both are in close proximity to one another the signal remains quenched; however, 
when Taq polymerase reads through and cleaves the 5’ fluorophore, the fluorescent dye is 
relieved of its close proximity to the quencher and is able to give off a signal that can be 
measured in real time (Schleinitz et al., 2011) (Figure 1.5) 
Kompetitive allele specific PCR (KASP) genotyping requires multiple forward 
primers with the base at the 5’ end specific for each possible outcome of the SNP and a 
universal reverse primer. The forward primers will bind the SNP site but will only be able 
to elongate if they bind with the correct complimentary base to the SNP. A probe, 
complimentary to the SNP sequence is then incorporated, a separate fluorescent dye for 
each SNP outcome, and the sequence is amplified, and with it the signal intensifies and can 
be quantified (Ayalew et al., 2019).  
RNase H2 enzyme-based amplification (rHAMP) also utilizes allele specific 
primers with a 3’ blocking modification consisting of an RNA base. The assay also utilizes 
a set of universal primers that flank the SNP region and universal probes. The allele specific 
primer will bind to the complimentary SNP sequence and RNase H2 will cleave the RNA 
3’ modification to allow for extension by Taq polymerase. A tail sequence is incorporated 
in subsequent cycles and a universal probe recognizes the tail sequence to bind, and through 
extension, a signal is generated (Ayalew et al., 2019). 
Overall, Taqman SNP genotyping allows only up to 6 bp sequences to be genotyped 
offering less flexibility in assay design compared to KASP or rHAMP. The Taqman and 
KASP techniques lack the modified 3’ end primers that rHAMP technology utilizes to 
reduce non-specific binding and unwanted dimerization, therefore, allelic discrimination is 
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more accurate and defined in rHAMP techniques compared to KASP and Taqman (Ayalew 
et al., 2019). Taqman is the most expensive of the three genotyping assays at ~$250 for 
2,000 reactions compared to KASP and rHAMP at less than $100 for 5,000 reactions 
including primers and probes. Master mix is sold separately and costs ~$550 for 2,000 
reactions for Taqman assays and ~$1000 for KASP and rHAMP for 10,000 reactions. 
Lastly, all assays utilize minimal DNA input with Taqman and KASP at a required 5 ng 
DNA, and rHAMP at 20 ng (Ayalew et al., 2019).  
Other methods that include PCR are single strand conformation polymorphism 
analysis (SSCP) and restriction fragment length polymorphism (RFLP) analysis. The SSCP 
analysis can be used to identify polymorphism at any position (Orita et al., 1989; Rajatileka 
et al., 2014). Methods include isolating DNA, amplification of the sequence of interest and 
denaturation of products in a formamide solution. When the products are denatured, they 
will reveal different conformational shapes due to polymorphisms they contain that will 
affect how they migrate through a non-denaturing gel. These patterns can then be used to 
identify mutations in the DNA (Orita et al., 1989). Cost is relatively low for this method of 
genotyping however the use of formamide poses some extra risk in performing this 
procedure. 
The RFLP analysis takes advantage of a mutation that may or may not abolish a 
restriction site.  Polymerase chain reaction is used to amplify the region containing the SNP 
of interest. The product is purified and digested with the restriction enzyme that will cut at 
the restriction site where the SNP is located, resulting in multiple fragments that vary in 
size. The band patterns that result are used for SNP genotyping (Maeda et al., 1990). 
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Considerations for this method include sample number and cost, as some of the enzymes 
will not tolerate the taq polymerase in the original PCR reaction and cost is incurred for 
PCR cleanup for each reaction prior to digestion. Since there are two reactions, PCR and 
digestion, there is also concern of contamination from sample to sample. 
 Sanger sequencing is also a powerful tool to identify SNPs. This method works 
through production of fragments that contain dideoxynucleotides at the 3’ end. These 
fragments are separated by capillary electrophoresis which will separate each base by 
molecular weight. Each is tagged with a different colored fluorescent dye at the 3’ end for 
identification by base calls. Each base will be identified by a different color fluorescence 
as they pass through capillary electrophoresis (Imelfort et al., 2009). The base calls 
resemble peaks of fluorescence that can be used to identify SNPs by varying color and 
intensity of the peak. Single nucleotide polymorphisms will show overlap of signal or base 
calls for heterozygotes and a single signal for homozygotes. Although Sanger sequencing 
was once considered and may still be largely considered the hallmark of this technology, 
NGS has largely replaced this technique, as larger data sets can be collected for a fraction 
of the price, $0.25 per SNP compared to $2.95 for Sanger sequencing. Aside from price, 
platforms such as Illumina are also only able to perform short reads while Sanger 
sequencing can perform at over 500 nt (Imelfort et al., 2009).  
Overall, when choosing a method for genotyping the main considerations are time, 
cost, sample abundance, and abundance of SNPs being studied. The NGS and microarray 
options are much more expensive but provide high throughput data allowing for detection 
of thousands of SNPs in many samples within a short time frame (Goodwin, McPherson, 
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and McCombie, 2016). The PCR based assays are also capable of processing thousands of 
samples as most assays are sold as sets of 2,000-5,000 reactions and are performed in plate 
format; however, the region of interest needs to be known prior unlike high throughput 
methods that allow for screening of the entire genome for SNPs. The cost for FRET-based 
qPCR assays are higher than the cost of SSCP or RFLP; however, the FRET based assays 
are much less labor intensive (Chen and Sullivan, 2003). Other considerations include cost 
of and access to equipment for high throughput processing and cost of sending samples out 
of the laboratory for processing, which can take some time. This extra time and cost can 
be worth the vast amount of data generated by high throughput screening for SNPs if the 
goal is to identify large quantities of SNPs across a given population or SNPs across the 
entire genome.  
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Figure B.1 Genotyping using fluorescence resonance energy transfer (FRET) 
technology (Taqman custom SNP genotyping assay).  
 (A) Primers are utilized to amplify a region containing a single nucleotide 
polymorphism (SNP) of interest. Custom probes that are complimentary to the SNP 
sequence, each contain a possible allele outcome for the SNP site with a fluorophore 
attached to the 5’ end and a quencher attached to the 3’ end of each probe. When the 
fluorophore is in close proximity to one another the signal remains quenched. (B) When a 
probe is complimentary to the SNP allele, Taq polymerase reads through and incorporates 
the probe while the 5’ fluorophore is cleaved, displacing the fluorescent dye molecule and 
giving off a signal. (C) If the probe hybridizes only partially to the DNA due to a mismatch 
to the SNP allele, the intact labeled probe will become displaced and no signal is obtained. 
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